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Agonisti ed antagonisti peptidici o peptidomimetici per il recettore delle 
chemochine CXCR4 come marcatore biologico e target diagnostico-terapeutico 
 
Riassunto 
 
1. Introduzione 
Le chemochine costituiscono una famiglia di piccole proteine (8-10 kDa) con attività 
chemotattica. Esse si dividono in quattro sottofamiglie: CXC (alpha), CC (beta), C 
(gamma) e CXXXC(delta), a seconda della posizione delle prime due cisteine (Fig. 1)  [1]. 
Il meccanismo d'azione delle chemochine prevede il legame a specifici recettori 
transmembrana 
accoppiati a proteine G 
(GPCR).  
I GPCR sono 
caratterizzati da un 
comune dominio centrale 
costituito da sette eliche 
transmembranarie, 
connesse da tre loop 
intracellulari (i1, i2 ed i3) e 
da tre loop extracellulari (e1, e2 ed e3) (Fig 2). Due residui di cisteina (uno sull'elica 3 e 
l'altro sul loop e2), che sono conservati nella maggior parte dei GPCR, formano un ponte 
disolfuro importante per l'impacchettamento e la stabilizzazione del dominio elicoidale. A 
parte la variabilità di sequenza, i GPCR differiscono nella lunghezza e nella funzione del 
dominio extracellulare N-terminale, del dominio C-
terminale intracelullare e dei loop intracellulari. 
Le chemochine sono prodotte e rilasciate da una 
grande varietà di cellule durante la fase iniziale della 
risposta immunitaria a lesioni, allergeni, antigeni e 
microorganismi patogeni. Esse svolgono un ruolo 
centrale nei processi infiammatori, promuovendo 
l'attivazione e la migrazione dei leucociti presso i 
focolai di infiammazione. Le chemochine sono 
altresì coinvolte nell'angiogenesi e nell'ematopoiesi. 
Il CXCL-12 (o ―Stromal Derived Factor‖ SDF-1α), un 
membro della famiglia CXC (Cys-X-Cys), è prodotto 
nei linfonodi, polmoni, fegato e nel midollo osseo ed 
è un potente chemoattrattore dei linfociti T, neutrofili 
e cellule staminali ematopoietiche CD34+ e 
rappresenta l'unico ligando naturale noto del recettore CXCR4, appartenente alla classe 
della rodopsina della superfamiglia dei recettori GPCR. 
Recentemente è stato trovato che le cellule tumorali sovraesprimenti una serie di recettori 
per chemochine, attraverso l‘interazione con specifici ligandi prodotti nei siti di sviluppo 
delle metastasi, determinano la progressione sia del tumore primario che la destinazione 
finale delle metastasi. Diversi lavori descrivono la presenza del recettore CXCR4 e della 
relativa chemochina SDF-1α in numerose neoplasie umane, quali il tumore mammario, il 
melanoma, il carcinoma del colon, il carcinoma renale, del colon retto, del polmone [2]. In 
particolare, è stato enfatizzato il ruolo dell‘asse CXCR4-CXCL12 nell‘homing midollare e 
quindi nella mobilizzazione di precursori ematopoietici.  Nel midollo osseo e nei tessuti 
linfoidi le cellule tumorali sono in diretto contatto con le cellule stromali (stromal cells 
and/or ―nurselike cells‖) che costituiscono il microambiente relativo a diversi stadi della 
malattia. CXCL12 ha un ampio spettro di effetti in relazione allo sviluppo delle neoplasie, 
CX3C:      ……………CXXXC………………………………………………………  CX3CL1   
CXC:       ……………CX__C………………………………………………………  CXCL#        
CC:        ……………C___C………………………………………………………  CCL#     
C:         ………………………C………………………………………………………  XCL#    
Classe Nome
Dominio N-terminale
Fig.1 Classificazione delle chemochine endogene. 
Fig. 2 Rappresentazione schematica dei 
recettori GPCR. 
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ma il ruolo primario del CXCL12 è nella mobilizzazione di precursori ematopoietici e nella 
definizione di una nicchia di cellule staminali neoplastiche in cui l‘elevata concentrazione di 
CXCL12 richiama una sottopopolazione di cellule altamente tumorigeniche e ne promuove 
sopravvivenza, proliferazione, angiogenesi e diffusione metastatica. 
L‘importanza dei recettori delle chemochine in vivo è stata dimostrata dall‘utilizzo di 
anticorpi specifici per il recettore CXCR4 che significativamente riducono la formazione di 
metastasi nei linfonodi e nei polmoni in topi immunodeficienti [3]. 
CXCR4 è espresso costitutivamente in maniera diffusa in una varietà di tessuti sani, tra cui 
il tessuto linfatico, il tessuto cerebrale, la milza e lo stomaco. Inoltre tale recettore è anche 
espresso in cellule staminali normali di diversi tessuti incluse le cellule staminali 
mammarie. Questo suggerisce che CXCR4 è essenziale per quelle cellule staminali che 
sembrano essere le progenitrici delle cellule tumorali. Il segnale prodotto dall‘interazione di 
questo recettore produce tutta una serie di molecole coinvolte in processi chiave come il 
controllo del ciclo cellulare e l‘ apoptosi. 
La formazione di metastasi richiede diversi passaggi distinti, tra cui il raggiungimento dei 
vasi sanguigni da parte di cellule tumorali, la sopravvivenza nella circolazione, il 
movimento verso un organo secondario, l‘adesione e la proliferazione delle cellule tumorali 
nell‘organo e tessuto bersaglio. Secondo studi  effettuati in vitro ognuno di questi stadi è 
potenzialmente regolato da segnali da parte di CXCR4. L‘asse CXCR4/ SDF-1α, infatti, 
attiva una serie di cascate metaboliche che portano alla produzione di molecole che 
giocano un ruolo chiave nei processi appena elencati. Ad esempio tale interazione stimola 
la via del fosfatidilinositolo-3-chinasi che attiva la proteina chinasi AKT che porta 
all‘inibizione dell‘apoptosi e al prolungamento della vita cellulare in numerosi tipi di cranco. 
Tale proteina è anche implicata nella proliferazione cellulare e nella migrazione attraverso 
un gradiente di SDF-1α. La polimerizzazione dell‘actina, che determina la mobilità 
cellulare, e l‘attivazione di alcune proteine tiroxina chinasi della famiglia delle src, che 
attivano l‘adesione della cellula a componenti esterne, derivano dall‘ interazione CXCR4/ 
SDF-1α. Infine, anche il processo di angiogenesi sembra scaturire da tale interazione 
attraverso la non regolata produzione di VEGF (Vascular Endothelial Growth Factor) [4]. 
Da tali evidenze consegue che l‘asse CXCR4/ SDF-1α gioca un ruolo fondamentale nella 
diffusione e nella progressione di numerosi tipi di tumore, quindi, sia SDF-1 che CXCR4 
potrebbero essere utili bersagli di nuovi agenti terapeutici e diagnostici nell'ambito delle 
patologie tumorali. 
 
2. Premesse scientifiche ed obiettivi del progetto di dottorato 
Le strutture delle chemochine finora risolte sono molto simili e sono caratterizzate da un 
dominio centrale formato da tre β-strand con sopra adagiata un'elica C-terminale. Gli 
strand sono preceduti da una regione N-terminale, il motivo CXC o CC ed un loop esteso 
(chiamato N-loop). Diversi studi di relazione struttura-attività hanno evidenziato 
l'importanza del dominio N-terminale, del motivo disolfuro e dell'N-loop che precede il 
caratteristico dominio CXC della chemochina SDF1 per il legame e l'attivazione del 
recettore [5]. E‘ stato infatti ipotizzato un meccanismo di interazione a due stadi 
compatibile con le relazioni struttura-funzione trovate per altre chemochine, dove il motivo 
RFFESH (12-17) costituisce il primo contatto tra il recettore e il suo ligando permettendo 
cosi l‘accesso ad un sito più ingombrato. Infatti nel secondo stadio del processo di 
interazione i residui N-terminali 1-8, determinanti per l‘attivazione del recettore, 
interagiscono con le eliche transmembrana inducendo un cambiamento nella 
conformazione del recettore e, quindi, consentendo la trasmissione del segnale (Fig. 3) 
[6]. 
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Il CXCR4 è stato inoltre identificato come co-recettore per la fusione ed infezione delle 
cellule T da parte del virus HIV-1 [7]. L'ingresso del virus nella cellula ospite è mediato 
dall'interazione di alcune glicoproteine dell'involucro virale (gp120 e gp41) con recettori 
della cellula ospite (CD4 e CCR5 o CXCR4), attraverso una complessa sequenza di eventi 
molecolari.  
L‘antagonista più diffuso per il recettore CXCR4 è l‘ AMD3100 [8], una molecola biciclica 
inizialmente utilizzata nel trattamento dell‘ HIV. Sebbene l‘AMD3100 risulti un rapido ed 
efficiente agente mobilizzante, esso ha, tuttavia, rivelato in precedenti studi scarsa 
biodisponibilità, tossicità epatica, cardiaca e cerebrale.  Inoltre sono stati descritti diversi 
peptidi, quali il T140 e i suoi derivati, che mostrano una discreta attività antagonista verso 
il recettore CXCR4. Recentemente sono stati anche sviluppati peptidi ciclici, quali FC130, 
in modo da ottenere antagonisti a più basso peso molecolare rispetto al T140 [9]. 
Poiché CXCR4 e altri recettori per chemochine omologhi rappresentano bersagli 
promettenti e al momento è disponibile un numero limitato di molecole attive, spesso 
dotate di considerevoli effetti collaterali negativi, esiste una forte richiesta di nuove 
molecole dotate di incrementata attività biologica, azione selettiva sui differenti pathway 
associati ai recettori e, quindi, minori effetti collaterali. 
Sulla base di tali considerazioni, l‘attività di ricerca è stata focalizzata sulla progettazione, 
sintesi e valutazione dell‘attività biologica di nuovi ligandi peptidici dotati di una buona 
affinità verso il recettore CXCR4, in modo da essere utilizzati come agenti terapeutici, in 
grado di modulare le caratteristiche funzionali del recettore target, o come marker 
diagnostici per patologie tumorali. Individuato un motivo strutturale dotato di una buona 
affinità col recettore target e che possa essere utilizzato come templato per lo sviluppo di 
ligandi biologicamente attivi verso il CXCR4, come passo successivo, è stato elaborata 
una nuova strategia sintetica per la preparazione di aminoacidi modificati in catena laterale 
da usare come building block nella sintesi di peptidomimetici. 
 
3. Progettazione e sintesi di ligandi peptidici  
Il sarcoma di Kaposi (KS) è una lesione tumorale che insorge frequentemente negli 
individui immunodeficienti. L'herpesvirus associato al KS è l'agente infettivo responsabile 
della malattia e, sorprendentemente, codifica diverse proteine che possiedono una diretta 
controparte nel sistema immunitario, in particolare proteine ―chemokine-like‖ che hanno 
approssimativamente una identità del 40% rispetto alle chemochine umane. Per una di 
queste, vMIP-II, è stato dimostrato che lega ed inibisce recettori appartenenti alla classe 
CXC, CC e XC, bloccando il flusso di calcio attivato dai recettori CCR1, CCR2, CCR5, 
CCR8, CXCR4 e XCR1 [10]. Come per  SDF-1α, la regione N-terminale e l‘N-loop sono 
essenziali per l‘interazione recettoriale. In particolare è stato dimostrato che la regione N-
terminale (residui 1-10) da sola  è sufficiente per legare il recettore CXCR4 e per esplicare 
l'attività antagonista [11]. 
Fig. 3 Meccanismo di 
interazione ipotizzato per il 
complesso 
CXCR4/CXCL12. 
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Il confronto sequenza-struttura fra le 
regioni N-termiale di SDF1 e vMIP-II 
mostra la conservazione per un motivo 
strutturale associato ad una sequenza 
omologa, seppur invertita di senso 
(Fig.4). Tale motivo prevede i residui Ar-
X-R (riferito al senso di vMIP-II), dove  
Ar è un residuo aromatico e X è un 
anello aromatico o insaturo. In 
particolare la sequenza è R12-F-F14 per 
SDF1 e W5-H-R7 per vMIP-II.  
Ipotizzando per questa associazione 
sequenza-struttura un ruolo 
fondamentale nel binding e traendo 
spunto dalle sequenze e strutture 
disponibili, sono stati disegnati 18 
peptidi al fine di: 
 convalidare le ipotesi sulle relazioni sequenza-struttura-attività e, in particolare, 
sull'invarianza del senso della sequenza, 
 determinare i requisiti minimi di sequenza per l'attività biologica; 
 individuare e misurare le influenze sul binding complessivo di singoli residui e/o gruppi 
terminali. 
Un'analisi preliminare dei motivi individuati in SDF-1a e vMIP-II ha condotto al design di 
una prima generazione di peptidi in cui la conformazione desiderata sia favorita dalla 
formazione di ponti disolfuro, e il motivo di binding sia limitato a soli residui aromatici, o 
anelli insaturi, e uno o due basici (Fig. 5). I motivi di residui aromatici sono stati derivati 
dalle sequenze di SDF-1α e vMIP-II, introducendo variazioni sulla natura del secondo 
residuo aromatico nelle sequenze di vMIP-II e variando anche il verso del peptide e la 
terminazione ai due estremi.  
Tutti i peptidi sono stati sintetizzati in fase solida utilizzando i protocolli della chimica 
Fmoc. Il primo amminoacido è stato 
legato alla resina seguendo i 
protocolli standard riportati in 
letteratura [12] e l‘efficienza di tale 
reazione è stata valutata mediante 
test Fmoc. Le reazioni di 
accoppiamento di tutti gli 
aminoacidi sono state effettuate  
due volte per 30 minuti in DMF, 
utilizzando un eccesso di quattro 
equivalenti per ogni amminoacido, 
PyBop e HOBt come attivanti e 
DIPEA come base. 
Il distacco dei peptidi dal supporto 
solido e la contemporanea 
rimozione di gruppi protettori 
presenti in catena laterale di 
ciascun aminoacido è stata 
eseguita sospendendo il peptide-
resina in una soluzione di acido 
trifluoroacetico contenente acqua 
ed etandiolo come scavinger. A 
H-Cys-Trp-His-Arg-Cys-OH
H-Cys-Phe-Phe-Arg-Cys-OH 
H-Cys-Trp-Tyr-Arg-Cys-OH 
H-Cys-Trp-Trp-Arg-Cys-OH 
vMIP-II-mimetic (X-X-Arg) 
Ac-Cys-Trp-His-Arg-Cys-OH
Ac-Cys-Phe-Phe-Arg-Cys-OH
Ac-Cys-Trp-Tyr-Arg-Cys-OH
Ac-Cys-Trp-His-Arg-Cys-NH2
Ac-Cys-Phe-Phe-Arg-Cys-NH2
Ac-Cys-Trp-Tyr-Arg-Cys-NH2 
H-Cys-Trp-His-Arg-Cys-NH2
H-Cys-Phe-Phe-Arg-Cys-NH2
H-Cys-Trp-Tyr-Arg-Cys-NH2 
SDF-1α mimetic (Arg-X-X) 
H-Cys-Trp-His-Arg-Cys-Ala-Arg-OH 
H-Cys-Trp-Tyr-Arg-Cys-Ala-Arg-OH 
H-Cys-Phe-Phe-Arg-Cys-Ala-Arg-OH 
H-Arg-Ala-Cys-Arg-His-Trp-Cys-OH 
H-Arg-Ala-Cys-Arg-Phe-Phe-Cys-OH 
H-Arg-Ala-Cys-Arg-Tyr-Trp-Cys-OH 
SDF-1
vMIP-II
RFF
WHR
C16
C9
C3
C14
C2
C10
C1
C18
C17
C6
C4
C12
C5
C8
C18
C11 C13
C15
C7
SDF-1, (1-17)
vMIP-II, (1-10)   LGAS            PDK
KPVSLSYR  CPC              ESHRFF
WHR
1 10 15
1 10
Sovrapposizione della la struttura tridimensionale
del motivo analogo di SDF-1α (verde) e vMIP-II
(magenta).
Fig.4 Sovrapposizione della struttura tridimensionale 
del motivo analogo di SDF-1α (verde) e vMIP-II 
(magenta). 
Fig.5  Sequenze aminoacidiche dei peptidi sintetizzati. 
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tale reazione, durata circa tre ore, è seguita un filtrazione allo scopo di eliminare le 
particelle di resina. Il filtrato è stato quindi concentrato ed il prodotto grezzo desiderato è 
stato isolato per precipitazione in etere freddo. La reazione di ciclizzazione, attraverso la 
formazione di un ponte disolfuro tra due residui di cisteina, è avvenuta sospendendo il 
peptide grezzo in una soluzione acquosa 0.1 M di NH4HCO3. Dopo quattro ore la miscela 
di reazione è stata concentrata e il prodotto desiderato è stato isolato, con buone rese e 
con alta purezza, attraverso l‘utilizzo di tecniche cromatografiche in fase inversa. 
I peptidi ammidati al C-terminale sono stati ottenuti utilizzando un resina Rink Amide come 
supporto solido, mentre i peptidi Acetilati  all‘ N-terminale sono stati ottenuti effettuando la 
reazione di acetilazione con anidride acetica e piridina prima di distaccare il peptide dalla 
resina. 
 
4. Saggi Biologici 
Allo scopo di valutare la capacità dei peptidi sintetizzati di modulare la funzionalità 
dell'asse CXCR4/SDF-1α, sono stati effettuati una serie di saggi biologici volti alla 
valutazione dei singoli eventi legati all'attivazione del recettore. Tali saggi hanno rilevato 
un‘attività biologica in vitro dei peptidi saggiati sia antagonista che agonista sull'attivazione 
del recettore. In particolare i saggi effettuati sono i seguenti: a) la valutazione 
citofluorimetrica della liberazione di Ca2+ in seguito alla stimolazione con SDF-1α; b) la 
modulazione della capacità migratoria cellulare in presenza o assenza dello specifico 
ligando SDF-1α; c) la modulazione dell‘attivazione di ERK-1,2; d) l‘inibizione del legame al 
recettore target da parte di specifici anticorpi coniugati a sonde fluorescenti. In particolare, 
alcuni dei peptidi sviluppati hanno mostrato azione antagonista, rispetto all‘induzione di 
migrazione indotta dal ligando, quasi comparabile all'inibitore meglio caratterizzato, 
AMD3100.  
I peptidi candidati che si sono rivelati inibenti in misura maggiore in tutti i saggi eseguiti 
sono: C16, C18 e C1. Su tali sequenze peptidiche è stato eseguito un saggio in vivo, 
adoperando un  modello murino di cellule di melanoma B16 precedentemente trasdotte 
con il recettore CXCR4 ed inoculate in un sistema di topo immunocompetente C57 Black. 
L‘analisi macroscopica e microscopica ha dimostrato un numero significativamente ridotto 
di metastasi polmonari nei gruppi di topi trattati con i peptidi C18, C16, C1. Nel dettaglio 
però la sequenza peptidica che ha mostrato maggiore capacità di ridurre il numero delle 
metastasi è C 18 (Fig. 6). 
Pertanto, i peptidi sviluppati, opportunamente selezionati, potrebbero essere impiegati 
come agenti antitumorali o per la diagnosi di neoplasie.  
  
 
 
 
 
 
 
 
 
 
 
 
 
d) Treated with C 16
a) Not injected b) Treated with PBS c) Treated with AMD3100
e) Treated with C18 a) Treated with C1
Fig.6 Metastasi polmonari dei 
topi trattati con i peptidi C18, 
C16, C1. 
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5. Sintesi di Coniugati chelante-peptide 
 Al fine di effettuare studi di imaging paramagnetico ed eventualmente radioattivo, sono 
stati progettati e sintetizzati coniugati in cui la sequenza di C18  è covalentemente legata 
ad un agente chelante. 
Allo scopo di esplorare la posizione di funzionalizzazione della sequenza peptidica più 
attiva, senza disturbare l‘interazione del peptide col recettore target, l‘agente chelante è 
stato inserito in due posizioni diverse della sequenza di C18: la catena laterale di un 
residuo di lisina inserito nel segmento peptidico (C19) e la sua estremità N-terminale (C20) 
(Schema 1).  
L‘agente chelante scelto è il DTPA ( Acido dietilentriamminopentacetico). Tale chelante è 
in grado di formare complessi stabili sia con il radioisotopo 111In+3, per applicazioni in 
medicina nucleare, sia con lo ione metallico Gd+3 per applicazioni come agente di 
contrasto NMRI.  
La sequenza peptidica di Ciclo-Phe 7 INV è stata modificata mediante sostituzione di Ala2 
con un residuo di Lys. L‘obiettivo è stato quello di legare il DTPA in catena laterale al 
residuo di lisina, in modo da essere sufficientemente distante dal backbone peptidico e 
quindi  non influenzarne il binding con il recettore. 
Il DTPA-tetra (t-Bu estere) è stato coniugato, attraverso il suo gruppo carbossilico libero, 
all‘ ε-NH2 della Lys2. Tale residuo di lisina è stato introdotto nella catena peptidica protetto 
con gruppo Fmoc sull‘alfa-NH2 e con un gruppo Mtt sull‘ ε-NH2 (Schema 1). Ciò ha 
consentito la rimozione selettiva del gruppo Mtt sull‘ ε-NH2 effettuata con ripetuti lavaggi 
della resina-peptide con una soluzione di 1%TFA in DCM, in presenza di TIS come 
scavenger. L‘ancoraggio del chelante è stato successivamente eseguito utilizzando lo 
stesso protocollo di attivazione (HBTU/HOBt/DIPEA) impiegato per gli accoppiamenti in 
fase solida.  
Successivamente, la sequenza di C18 è stata funzionalizzata con il chelante DTPA sull‘ 
NH2 terminale. Terminata la sintesi del segmento peptidico, dopo rimozione del gruppo 
Fmoc, l‘ancoraggio del chelante è stato eseguito utilizzando il protocollo di attivazione 
(HBTU/HOBt/DIPEA) impiegato per gli accoppiamenti degli aminoacidi (Schema 1). 
 
  
 
 
 
 
 
Schema 1. Strategia sintetica 
dei coniugati C19 e C20. 
 
 
 
 
 
 
 
 
 
 
 
 
 
I coniugati ottenuti C19 e C20, dopo essere stati ciclizzati e purificati con l‘utilizzo di 
tecniche cromatografiche in fase inversa, sono stati saggiati mediante saggio di inibizione 
Fmoc-Arg-Lys-Cys-Arg-Phe-Phe-Cys-NH2
__
1% TFA 
DCM
TIS
N
N
H
N
-OOC
-OOC
N
COO-
COO-
O
HN
H2N
O
H
N
O
N
H
S
O H
N
O
NH
NH
NH2
O
N
H O
H
N
S
O
OH
1. Fmoc-AA
    PyBop/HoBt/DIPEA
2. 20% Pip
Mtt
Fmoc-Arg-Lys-Cys-Arg-Phe-Phe-Cys-
NH2
1. 20% Pip
2. 2eq. DTPA(OtBu)4
   HBTU/HOBt/DIPEA
Fmoc-Arg-Lys-Cys-Arg-Phe-Phe-Cys-
NH
DTPA(OtBu)4
20% Pip
H-Arg-Lys-Cys-Arg-Phe-Phe-Cys-
NH
DTPA(OtBu)4
1. TFA/H20/EDT
2. NH4CO3 0.1 M
HN
NH
NH2
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del legame al recettore target di anticorpi fluorescenti. I risultai di tali studi hanno purtroppo 
evidenziato una ridotta affinità del coniutato C19 per il CXCR4 rispetto  all‘affinità mostrata 
dal solo peptide C18.  Per ciò che riguarda il coniugato C20, sono attualmente in corso gli 
esperimenti di binding che ci consentiranno di valutare se il composto conserva un‘affinità 
per il recettore utile agli scopi di utilizzo dello stesso coniugato come sonda in esami di 
imaging diagnostico. 
 
6. Progettazione e sintesi di peptidomimetici 
  La sequenza peptidica di C18 si è rivelata la più attiva nei saggi biologici effettuati sia in 
vivo che in vitro. In particolare, il motivo Arg-Phe-Phe del peptide in oggetto è stato 
individuato come nucleo farmacoforico, ossia principale motivo strutturale responsabile 
dell‘interazione con il recettore target. Ciò ha suggerito la possibilità di sintetizzare 
peptidomimetici di C18, che consentano di variare la disposizione spaziale dei residui 
aromatici del nucleo farmacoforico, in modo da stabilizzarne la conformazione bioattiva.   
E‘ stata progettata una libreria di 
peptidomimetici in cui i residui di 
Phe3 e Phe4 di C18 sono 
sostituiti con derivati di vari 
aminoacidi, quali Lys e i suoi 
omologhi inferiori, modificati in 
catena laterale mediante 
reazioni di N-alchilazione, che 
hanno consentito di introdurre 
diversi sostituenti aromatici 
(Fig. 7). La realizzazione di tali obiettivi ha previsto innanzitutto la messa a punto di una 
strategia di sintesi di building block da inserire nella sequenza peptidica.  
E‘ stata, quindi, elaborata una efficiente procedura sintetitica che permette di ottenere 
amminoacidi basici N-alchilati in catena laterale [13]. In particolare, Lys, Orn, Dab a Dap 
sono stati funzionalizzati in catena laterale mediante una procedura di N-alchilazione. Tale 
procedura risulta semplice, efficiente e riproducibile su scale superiori, in modo da poter 
utilizzare gli Nα-Fmoc amminoacidi alchilati ottenuti come building blocks da inserire nella 
sintesi dei peptidomimetici desiderati. Lo scopo è quello di sviluppare una procedura 
generale con condizione blande di N-alchilazione, che non influenzino né la stereochimica 
dell‘ aminoacido, né gli altri gruppi funzionali e/o protettori  presenti sul substrato da 
alchilare (α-COOH e Fmoc/Boc). 
Come mostrato nello 
schema 2, la strategia 
sintetica impiegata 
prevede il trattamento di 
ogni Nα-Fmoc 
amminoacido, 
opportunamente attivato 
in catena laterale col 
gruppo o-NBS e sciolto in 
DMF,  solo con 
l‘appropiato alogenuro 
alchilico e in presenza di 
setacci molecolari di 4 Ǻ 
come base blanda. Tale 
procedura porta a rese quantitative, permettendo così di utilizzare il composto ottenuto 
direttamente (senza passaggi di purificazione) per la fase successiva di assemblaggio del 
peptidomimetico. Al fine di rendere generale l‘utilizzo di tale metodologia, la procedura è 
Fmoc-HN
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O
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S
O
O
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+
n
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Fig. 7 Derivati N-alchilati di Dap, Dab, Orn e Lys 
Schema 2 Strategia sintetica dei building block N-alchilati 
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stata impiegata utilizzando diversi agenti alchilanti; la resa e i tempi di reazione sono 
descritti nella Tab.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tab 1. Rese e tempi di reazione dei building block sintetizzati. 
 
 
7. Conclusioni e prospettive future 
Il lavoro svolto durante il corso di dottorato ha portato allo sviluppo di ligandi peptidici 
alcuni dei quali hanno esibito un‘azione antagonista, rispetto all‘induzione di migrazione 
indotta dal ligando, quasi comparabile all'inibitore meglio caratterizzato (AMD3100) del 
recettore target CXCR4. Lo studio condotto in vivo relativo al saggio di metastasi 
polmonari di melanoma ha dimostrato un numero significativamente ridotto di metastasi 
polmonari nei gruppi di topi trattati con alcuni dei peptidi sviluppati. Pertanto, essi, 
opportunamente selezionati, potrebbero in futuro essere impiegati come agenti 
antitumorali o per la diagnosi di neoplasie.  
Inoltre, sono state messe a punto strategie di sintesi allo scopo di preparare aminoacidi 
modificati da utilizzare per la sintesi di una libreria di peptidomimetici. Lo scopo, infatti, è 
quello di introdurre motivi strutturali in grado di stabilizzare la conformazione bioattiva del 
peptide che si è rivelato più attivo nei saggi biologici eseguiti. Parallelamente, in futuro il 
lavoro di progettazione e sintesi sarà focalizzato sullo sviluppo di una seconda 
generazione di peptidi caratterizzati da strutture omo- o eterodimeriche. Tale obiettivo 
nasce dalle numerose evidenze sperimentali che hanno rilevato che frammenti peptidici 
della porzione N-terminale di SDF-1, già da soli attivi verso il recettore CXCR4, mostrano 
maggiore affinità ed attività se inseriti in omodimeri [5]. Su tali basi sarà quindi possibile 
utilizzare le sequenze più attive dei peptidi di prima generazione per sintetizzare una 
seconda generazione di antagonisti del recettore CXCR4 di natura omo- o etero dimerica.  
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Summary 
 
Chemokines are a family of small low molecular weight secreted cytokines that regulate 
cell migration by activating a set of G-protein-coupled receptors (GPCRs). Beside the 
physiologic role, chemokines and their receptors participate in numerous disease states, 
including HIV/AIDS, asthma, autoimmune diseases, and cancer. Over expression of 
CXCR4 receptor and over production of its only ligand, the chemokine CXCL12 (also 
called stromal cell-derived factor-1, SDF-1), was described in brain neoplasm, 
neuroblastoma cells, colorectal cancer, prostate cancer, melanoma,renal cell cancer, 
ovarian cancer, and others. Because it directs stem-cell homing and participates in nearly 
every aspect of cancer progressions, growth, metastasis and neovascularization, the 
CXCL12/CXCR4 signaling axis is of increasing interest for drug discovery. Among the 
CXCR4 inhibitors there are two major classes of CXCR4 antagonists, small-molecule 
antagonists (AMD3100 and its analogs) and peptidomimetics (T140 and its analogs).  
As for other chemokines, structure-activity studies of SDF-1 have shown the critical role of 
the N-terminal region for both receptor binding and activation and in particular the residues 
1-8 and 12-17, these last being located in the loop region.  
vMIP-II, a CC chemokine-like protein encoded by Kaposi's sarcoma-associated 
herpesvirus, binds and blocks chemokine receptors belonging to the CXC, CC and XC 
class, such as CCR1, CCR2. CCR5, CCR8, XCR1 and CXCR4. As for SDF-1, the N-
terminus and the N-loop are essential for receptor binding. In particular it was 
demonstrated that the N-terminus alone, encompassing residues 1-10, is sufficient for 
binding and antagonizing CXCR4 receptor. Therefore in this study we have focused on a 
sequence-structure comparison between the N-terminal regions of SDF-1 and vMIP-II, 
with the aim of looking for a possible common motif responsible for the binding to CXCR4. 
On the basis of this comparison, several cyclic peptides containing a putative common 
motif have been designed, studied by molecular dynamics simulations and then 
synthesized. The peptides differ in: a) nature of the aromatic residues; b) sequence sense; 
c) N- and C-termination, as all combinations of free, single- and double-protected (by 
acetylation and amidation) termini were tested on selected peptides; d) possible elongation 
at either peptide termini by a Arg-Ala sequence. Their activity has been tested by different 
essays addressing some of the many physiological and pathological functions of CXCR4 
receptor:  Binding through flow cytometry, modulation of  intracellular Ca2+ release, 
modulation of cell migration in presence or without specific ligand SDF-1 and Modulation 
of P-Erk activation. 
The pattern of biological responses elicited by these peptides was, heterogeneous 
demonstrating agonism, antagonism and no interference for the same peptide in different 
assays. These results cannot be explained simple models interaction receptor 
activation/inhibition and suggest more complex scenario considering  direct CXCL12-
peptide interactions and/or influence on symmetry, stoichiometry or structural variations of 
the homo- or hetero-oligomeric state of CXCR4 receptor. Among the peptides with 
consistent inhibitory activity on CXCR4 four peptides were identified: peptides C1, C16, 
C17 and C18. In particular peptide C16 is inhibitor in all the evaluated in vitro assays 
performed. Based on these results, the in vivo effect on metastases formation was tested. 
The peptides (C1, C16 and C18) significantly inhibited melanoma metastases and 
preliminary results showed that renal cancer cells xenograft  SN12C-pEGFP was 
significantly reduced in growth in the presence of peptides C1, C16 and C18.  
As a subsequent step, it was evaluated the possibility to develop peptide C18 derivative 
bearing a chelating agent able to coordinate radioactive metals for applications in cancer 
diagnosis by nuclear medicine techniques. In order to investigate the chelating agent site 
of linkage which does not interfere on the peptide-receptor interaction, two 
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diethylentriaminopentacetic acid (DTPA)-C18 conjugates were synthesized:  one carrying 
DTPA moiety covalently bound to petide N-terminus (C20) and one carrying the chelating 
moiety DTPA covalently bound to the epsilon-NH2 of a lysine residue which replaced  Ala2 
of C18 (C19).  
Before performing nuclear medicine imaging studies, C19 and C20 were evaluated for 
their ability to inhibit the specific antibody binding  to CXCR4. Both conjugates exhibited a 
reduced inhibiting activity, compared with that exerted by the only peptide sequence (C18). 
These results highlighted that the introduction of the chelating agent on the N-terminus, as 
well as on the lysine epsilon-NH2 group, can affect the binding process with the receptor 
target. We are currently exploring other peptide positions where to anchor the DTPA 
moiety. 
Since the pharmacophoric motif of the most active peptide sequence (C18) is 
characterized by aromatic rings and idrofobic residues, it is possible to project 
peptidomimetics in order to modulate the aromatic rings distance from the peptide 
backbone. In particular, Phe3 and Phe4 residues of C18 can be replaced by aminobenzilic 
derivatives, such as Nε-benzylated Lys and its shorter homologues, in order to evaluate 
the influence of  the more flexible pharmacoforic motif on the binding process. The final 
goal has been to  introduce conformational constraint into the peptide sequence by which 
it would be possible to stabilize the so-called 'bioactive' conformation, that is the peptide 
conformation required for receptor binding and activation. 
On these basis, we focused on an alternative and more practical synthetic strategy in 
solution and in solid phase in order to obtain modified amino acids  to be used as a 
building block in peptidomimetic synthesis. In particular  we performed the alkylation 
reaction on  several  Fmoc-amino acids, protected on their side chain, (Fmoc-Lys(P)-OH, 
Fmoc-Orn(P)-OH, Fmoc-Dab(P)-OH Fmoc-Dap(P)-OH) only in presence of 4 Ǻ molecular 
sieves and alkyl halides. This methodology was validated for different amino protecting 
groups, but the best results were obtained by using o-Ns protected Fmoc-amino acids. 
Furthermore, for the majority of the employed halides, the procedure is a one-pot 
synthesis which avoids the purification after each reaction step. As final step we verified 
the applicability of building block synthesized by introducing one of them into a peptide 
sequence using the standard Fmoc-based solid phase protocol.  
Data complied and the methodology developed open new perspectives in obtaining more 
selective compounds toward different biological pathways involving CXCR4 receptor. In 
this regard, the forthcoming activity will be focused on the development of peptidomimetics 
that allow stabilizing conformation required for receptor binding and activation. Moreover, 
dimers of the most active peptides will be also synthesized and tested for their biological 
activity, in order to evaluate any potential improvement of it compared with the activity 
exerted by the corresponding monomeric peptide sequence. 
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Abbreviation 
 
Ac2O  Acetic anhydride 
AKT  Adenosine kinasi transfer 
AIDS  Acquired immune deficiency syndrome 
Alloc  Allyloxycarbonyl 
Boc  Butossicarbonyl 
BSA  Bovine serum albumin 
cf  Amide group C-terminations 
cf  Free carboxylate C-terminations 
CLL  Chronic lymphocytic leukaemia 
DBU  1,8- Diazabicyclo[5.4.0]undec-7-ene 
DCM  Dicloromethan 
DIPEA  Diisopropilethylammina 
DTPA  Diethylentriaminopentacetic 
DMF  Dimethylformammide 
DMSO  Dimethyl sulfoxide 
ECM  Extracellular matrix 
EDT  Ethanedithiol 
EDTA  Ethylenediaminetetraacetic acid 
EGTA  Ethylene glycol tetraacetic acid 
Env  Viral envelope 
ERK  Extracellular Signal-Regulated Protein kinase 
ESI-MS  Electrospray Ionization-Mass Spectrometry 
FCS  Fetal calf serum 
FBS  Precolostral bovine Serum 
Fmoc  9-Fluorenilmetossicarbonyl 
GPCRs  G protein coupled receptors 
HATU  2-(1H-9-Azobenzotriazole-1-yl)-1,1,3,3,-tetramethyluronium 
HCl  Cloridric acid 
HBTU  2-(1H-Benzotriazole-1-ile)-1,1,3,3-tetramethyluronium 
esafluoro phosphate 
HIF  Hypoxia-inducible factor 
HIV-1  Human immunodeficiency virus 
HL-60 cells  Human promyelocytic leukemia cells 
HOBt  Hydroxybenzotriazole 
HRMS  High resolution mass spectrometry 
HSC  Haematopoietic stem cells 
IMDM  Iscove's Modified Dulbecco's Media 
K2CO3  Potassium carbonate 
LC-ES-MS  Liquid chromatography-electrospray mas 
LC-MS  Liquid chromatography-mass spectrometry 
LiOH  Lithium hydroxide 
MAPKinase  Mitogen-Activated Protein Kinase 
MBHA  4-methylbenzhydrylamine 
MD  Molecular dynamics 
MEK  Mitogen extracellular signal regulated kinase 
MMP  Matrix Metalloproteinases 
MS  Molecular sieves 
Mtt  Methyl trityl group 
nac  Acetyl group peptide N-terminations 
naf  Free amino group peptide N-terminations 
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NaH  Sodium hydrure 
NAMD  Not Another Molecular Dynamics program 
NaOH  Sodium hydroxide 
NK  Natural killer 
NH4HCO3  Ammonium Bicarbonate 
NMR  Nuclear magnetic resonance spectroscopy 
NOE  Nuclear Overhauser Effect. 
Ns  Nitrobenzensulfonyl 
OtBu  O-tert-Butyl 
PDB  Protein data bank 
Pbf  2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-ylsulfonyl 
Pip  Piperidine 
PyBop  benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate 
QTOF  Quadrupole time-of-flight 
RAFT  Related adhesion focal tyrosine kinase 
r.m.s.d.  Root mean square deviation 
RP-HPLC  Reversed phase high performance liquid chromatography 
RPMI  Roswell Park Memorial Institute medium 
SDF-1  Stromal cell-derived factor-1 
tBu  t-Butyl 
TIS  Triisopropylsilane 
TFA  Trifluoroacetic acid  
TH2  T-helper 2 
Trt  Trityl 
VEGF  Vascular Endothelial Growth factor  
vMIP-II  Viral macrophage inflammatory protein-II 
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1. Introduction 
 
 
1.1 The biological role of chemokines  
 
Chemokines comprise a family of low molecular weight chemotactic cytokines, which are 
implicated in many biological processes, such as migration of leukocytes, embryogenesis, 
angiogenesis, hematopoiesis and atherosclerosis [1-3]. Chemokine signalling results in the 
transcription of target genes that are involved in cell invasion, motility, interactions with the 
extracellular matrix (ECM) and survival [4]. These chemotactic cytokines can be classified 
into two main groups based on their function and pattern of expression: homeostatic and 
inflammatory chemokines. The homeostatic chemokines (examples in this group include 
CCL21, CCL19, CXCL13, CXCL12 and TECK) are constitutively expressed in certain cell 
types and tissues, and play a vital role in the development and maintenance (homeostasis) 
of the hematopoietic and the immune system. In contrast, the inflammatory chemokines 
(typical examples include CXCL8, CCL24, CCL2, CXCL10, CCL4 and CCL5) are not 
constitutively expressed but are inducible and up-regulated by inflammatory stimuli. Their 
expression is tightly controlled by the local pro-inflammatory cytokine milieu. Directed 
migration of cells that express the appropriate chemokine receptor occurs along a 
chemical gradient of ligand — known as the chemokine gradient — allowing cells to move 
towards high local concentrations of chemokines (Fig. 1). 
 
 
 Figure 1 Leukocyte 
(immune cell) adhesion 
and migration along and 
penetration through the 
wall of a blood vessel 
under the influence of a 
CK gradient and vascular 
sheer flow.  
 
 
The small (8–10 kDa) chemokine proteins are classified into four highly conserved groups 
— CXC, CC, C and CX3C — depending on the positioning of the conserved cysteines in 
the aminoterminal part of these small inducible proteins [3]. The CXC or α subgroup is 
further subdivided in ELR+ and ELR- chemokines, based on the presence or absence of 
the tripeptide glutamic acid-leucine-arginine (the ‗ELR‘ motif) preceding the CXC domain. 
The ELR+ CXC chemokines, such as interleukin-8 (CXCL8/IL-8), are angiogenic, whereas 
most ELR- CXC chemokines, like platelet factor-4 (CXCL4/PF-4) inhibit angiogenesis [5]. 
This ‗ELR‘ motif appears to be important in ligand/receptor interactions on neutrophils [6–
8]. An exception of the relation between the ‗ELR‘ motif and angiogenesis is CXCL12/SDF-
1, an angiogenic ELR- CXC chemokine. 
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Figure 2  The chemokine wheel. This 
illustration explains the ligand-binding 
patterns of the seven-transmembrane 
domain G-protein-coupled human 
chemokine receptors. Receptors 
CXCR1–CXCR3, CCR1–CCR5, CCR7, 
CCR8, CCR10 and XCR1 all bind several 
chemokines. By contrast, CCR6, CCR9, 
CX3CR1 and CXCR4–CXCR6 bind only 
one ligand each. Duffy and D6 are 
considered to be ‗deceptors‘, as they bind 
ligands but do not signal, thereby acting 
as a negative feedback for chemokine 
responses. 
 
 
 
More than 50 chemokines have been discovered so far (Fig. 2); most, if not all chemokines 
activate leukocytes through binding to G protein-coupled seven transmembrane-domain 
receptors (GPCR) designated CXCR or CCR [9,10]. There are approximately 20 
chemokine receptors identified [2]. In general, these receptors, which belong to the G-
protein-coupled receptor family, bind to more than one type of chemokine (FIG. 2). 
However, six receptors bind to only one cytokine: CXCR4, CXCR5, CXCR6, CCR6, CCR9 
and CX3CR1. The profile of chemokine-receptor expression on an individual cell is 
determined by its lineage, stage of differentiation, and microenvironmental factors such as 
chemokine concentration, the presence of inflammatory cytokines and HYPOXIA. 
Chemokine receptors are present on many different cell types. Initially, these receptors 
were identified on leukocytes, where they were found to play an important role in the 
homing of such cells to sites of inflammation [11]. However, during the past few years, 
hematopoietic and nonhematopoietic cells have been found to express receptors for 
various chemokines that are constitutively expressed in distinct tissue microenvironments. 
The interactions between such receptors and their respective chemokines help coordinate 
the trafficking and organization of cells within various tissue compartments [12,13]. 
Lymphocytes trafficking between blood and secondary lymphoid tissues, for example, is a 
nonrandom process that is regulated by tissue-specific expression of chemokines [14]. 
Circulating blood lymphocytes interact transiently and reversibly with vascular endothelium 
through adhesion molecules (selectins, integrins) in a process called rolling. Chemokines 
on the luminal endothelial surface can activate chemokine receptors on the rolling cells, 
which triggers integrin activation[15]. This results in the arrest, firm adhesion, and 
transendothelial migration into tissues where chemokine gradients direct localization and 
retention of the cells [16]. These steps, collectively referred to as ―homing,‖ are essential 
for normal development of the organism, organization and function of the immune system, 
and tissue replacement. There is growing evidence that these physiologic mechanisms of 
tissue-specific recruitment also are functional in neoplastic cells. 
In addition, these GPCRs may account for the angiogenic or angiostatic action of 
chemokines. Indeed, triggering of CXCR2 by ELR+ CXC chemokines or CXCR4 by 
CXCL12/SDF-1 causes angiogenesis, whereas CXCR3 is an ‗angiostatic‘ receptor for 
some ELR- CXC chemokines [17,18]. 
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1.2 The chemokines involvement in cancers 
 
Chemokines are best known for inducing directional cellular migration, particularly of 
leukocytes during inflammation. Prolonged inflammation is thought to facilitate 
carcinogenesis by providing a microenvironment that is ideal for tumor cell development 
and growth. 
The pattern of chemokine receptor and ligand expression in a tissue generally correlates 
with the numbers and types of infiltrating cell that are present. The chemokine gradient 
that attracts infiltrating cells can be created by different cell populations in a tissue. In 
infections, the first cells that produce chemokines are probably tissue leukocytes, but 
fibroblasts, endothelial cells and epithelial cells (both normal and malignant) are all able to 
produce chemokines and generate a chemokine gradient. Although originally identified on 
leukocytes, functional chemokine receptors are also found on endothelial cells [19] and on 
some epithelial cells, particularly those that have been malignantly transformed [20-22].   
Chemokines affect tumor development indirectly by influencing angiogenesis, tumor–
leukocyte interactions, as well as directly by influencing tumor transformation, survival and 
growth, invasion and metastasis. The role played by chemokines is rather complex as 
some chemokines may favor tumor growth and progression, while others may enhance 
anti-tumor immunity. Solid tumors contain in addition to tumor cells, also various types of 
stromal cells, such as fibroblasts and endothelial cells. Moreover, tumors are infiltrated by 
inflammatory cells, including neutrophils, macrophages and lymphocytes. Tumor cells, 
stromal cells, as well as the tumor-associated leukocytes contribute to the local production 
of chemokines inside the tumor. In addition, tumor-derived chemokines further determine 
the influx of leukocytes into the tumor [23]. In this way, chemokines can stimulate or inhibit 
tumor development in an autocrine fashion by attracting cells with pro- or anti-tumoral 
activities, respectively (Figure. 3). Tumor-associated neutrophils and macrophages may 
favor tumor progression by secreting matrix degrading enzymes and growth factors, 
respectively [24,25]. In addition, macrophages have a remarkable degree of plasticity with 
a ‗switch‘ in phenotype during tumor progression [26]. Alternatively, tumor infiltrating 
cytotoxic T lymphocytes and NK cells are rather detrimental for tumor development [27]. 
Chemokines can also indirectly affect tumor growth by their angiogenic or angiostatic 
activity. Angiogenesis, the formation of new blood vessels from established ones, is an 
essential biological event during physiological and pathological processes, like 
embryogenesis, wound repair and tumor growth [28]. Angiogenesis is a complex process 
in which numerous stimulatory and inhibitory signals, such as integrins, angiopoietins, 
chemokines, oxygen sensors, growth factors, extracellular matrix proteins, and many other 
molecules are involved [29–31]. This delicate balance between angiostatic and angiogenic 
factors is strictly regulated. Tumor growth occurs when the equilibrium between angiogenic 
and angiostatic factors is disturbed in favor of the angiogenic factors. 
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Figure 3 Role of chemokines and their receptors in the tumor environment. Solid tumors contain various 
types of stromal cells, such as fibroblasts and endothelial cells. All these cell types are good producers of 
chemokines, regulating the migration of leukocytes. Leukocyte traffic is a highly coordinated multistep 
process. Briefly, leukocytes roll along the endothelium and chemokines bind leukocytes via their Gprotein-
coupled receptor. As a result, the leukocytes firmly attach to the endothelial cell layer. Finally, leukocytes 
transgress the endothelium and migrate into the underlying chemokine producing tissue in response to the 
chemokine gradient. As a result the tumor is infiltrated by inflammatory cells, including neutrophils, 
macrophages, T lymphocytes and dendritic cells. Indeed, all the ELR+ CXC chemokines attract CXCR2 
expressing pro-tumoral neutrophils, loaded with proteases. In contrast, some ELR- CXC chemokines, like the 
CXCR3 ligands CXCL9/Mig, CXCL10/IP-10 and CXCL11/I-TAC, attract activated CXCR3 T lymphocytes and 
NK cells, which might exert anti-tumoral (cytotoxic) activity. The production of chemokines by tumor cells, 
normal stroma and leukocytes also affects the process of angiogenesis by their angiogenic (the CXCR2 
ligands CXCL1,2,3/GRO-,a,b,c CXCL5/ENA-78, CXCL6/GCP-2, CXCL7/NAP-2, CXCL8/IL-8 and the CXCR4 
agonist CXCL12/SDF) or angiostatic (CXCL4/PF-4, CXCL4L1/PF-4var, CXCL9/Mig, CXCL10/IP-10, 
CXCL11/I-TAC) properties. The formation of new blood vessels is important in tumorigenesis to provide 
oxygen and nutrients and to stimulate the process of metastasis. Further, the CXCR4-CXCL12/SDF-1 
receptor–ligand axis is involved in the directed migration of tumor cells into metastatic sites. 
 
 
1.2.1 A role for chemokine receptors in cancer metastasis 
 
In many cancers, metastasis is the leading cause of mortality. Despite extensive research, 
the precise mechanisms by which cancer cells are disseminated to sites distant from the 
primary tumor are not fully understood. While the chemokine-mediated cell migration of 
leukocytes has long been known, it has only recently been found that tumor cells may 
utilize similar mechanisms during cancer metastasis [32]. It has been proposed that 
subsets of chemokine receptors are expressed by certain tumor cells and that specific 
chemokines are highly expressed at sites of cancer metastasis, thus suggesting that 
specific combinations of chemokines and chemokine receptors determine the final 
destination of metastatic tumor cells [23,33,34]. 
Infiltrating leukocytes are not the only cells that respond to chemokine gradients in 
cancers; cancer cells themselves can express chemokine receptors and respond to 
18 
 
chemokine gradients[16,34]. In fact, organ-specific metastasis might be governed, in part, 
by interactions between chemokine receptors on cancer cells with metastatic potential and 
chemokine gradients in target organs. There are similarities, for instance, between the 
transport of dendritic cells to lymph nodes, which is regulated by chemokine gradients, and 
the lymphatic spread of cancer cells [35]. This concept is supported by several reports, 
which describe the expression of a distinct non-random pattern of subsets of functionally 
active chemokine receptors, such as CXCR3 and CXCR4 in human melanoma cells[36, 
37] CXCR4 in metastatic breast cancer cells [20], and CCR7 and CCR10 in skin 
metastases [20]. 
Other evidence for the role of chemokine receptors in cancer metastasis include the 
findings that CCR5 is expressed on stromal cells and thereby promotes pulmonary 
metastasis [38] and that the upregulation of CXCR4 is essential for HER2-mediated breast 
tumor metastasis [39]. Moreover, the relevance of chemokine receptors in vivo was 
demonstrated by using CXCR4- specific antibodies, which significantly reduced the 
formation of lymph node and lung metastases in immunodeficient mice [20] and by 
studying CCR5 knockout mice (CCR5-/-), which developed fewer metastases[38]. 
However, the chemokine receptor that is most commonly found on human and murine 
cancer cells is the CXC receptor CXCR4 (Table 1).  
 
Table 1. Some of the chemokine receptors that are expressed on cancer cell 
 
Chemokine 
receptor 
Cancer cell expression Normal-cell expression 
CXCR4 23 different haematopoietic and 
solid cancers* 
HSC, thymocytes, T cells, B cells, immature 
and mature dendritic cells, some endothelium, 
macrophages and neutrophils 
CCR3 T-cell leukaemia T cells, basophils, eosinophils and plasma cells 
CCR4 T-cell leukaemia Thymocytes, NK cell, immature dendritic cells, 
skin-homing T cells and TH2 T cells 
CCR5 Breast cancer cell line Thymocytes, B lymphocites, immature and 
mature dendritic cells and macrophages  
CCR7 Breast cancer, CCL, gastric cancer, 
non-small-cell lung and 
oesophageal cancer 
B cells, T cells and mature dendritic cells 
CCR10 Melanoma Plasma cells and skin-homing T cells 
CXCR2 Melanoma Macrophages, eosinophils and neutrophils 
*Breast cancer, ovarian cancer, glioma, pancreatic cancer, prostate cancer, acute myeloid leukaemia, B-
chronic lymphocytic leukaemia, B-lineage acute lymphocytic leukaemia, non-Hodgkin‘s lymphoma, 
intraocular lymphoma, follicular centre lymphoma, chronic myelogenous leukaemia, multiple myeloma, 
thyroid cancer, colorectal cancer, squamous-cell carcinoma, neuroblastoma, renal cancer, astrocytoma, 
rhabdomyosarcoma, small-cell lung cancer, melanoma and cervical cancer. CLL, chronic lymphocytic 
leukaemia; HSC, haematopoietic stem cells; NK, natural killer; TH2, T-helper 2. 
 
 
 T. CXCR4 plays a critical role in the homing of cancer cells to distant sites [40, 20] by 
binding to its ligand CXCL12, which is highly expressed where metastastic lesions are 
commonly observed (Figure 4) [40, 41].  
Increased CXCR4 expression is associated with an aggressive phenotype since 
metastases frequently exhibit increased CXCR4 receptor expression compared with the 
primary lesion [42, 43]. Similarly, elevated CXCR4 expression in estrogen and progestin 
receptor–negative breast cancers and triple negative breast cancers is closely associated 
with lymph node metastasis [44]. Preclinical and clinical studies have detected high 
concentrations of CXCR4 receptors in the primary brain tumors compared with normal 
brain parenchyma [45, 46]. The invading regions of glioblastomas and satellite tumors, 
19 
 
which are the primary foci of recurrence, have been observed to express high levels of 
CXCR4 [47]. Tissue microarray analyses of patient biopsies have shown that nuclear 
staining for CXCR4 increases with tumor grade [48] and that elevated CXCR4 expression 
levels are associated with poor survival in patients with breast cancer [49-51]. CXCR4 
expression has therefore been proposed as a prognostic factor in several cancers 
including brain, breast, colon, prostate, kidney, melanoma, and osteosarcoma and 
considered a therapeutic target because of its role in tumor development, growth, and 
metastasis [52-56].  
 
 
Figure 4 Different aspects of 
cancer progression where 
chemokines and their receptors 
may play a primary role: growth 
of the primary tumor, 
angiogenesis (cell migration of 
endothelial precursors), 
metastasis, and growth survival 
of the metastasized cells which 
is probably the least efficient 
step in the metastatic process.  
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2.2 The role of the CXCR4–CXCL12 axis in cancer  
 
Tumour cells from at least 23 different types of human cancers of epithelial, mesenchymal 
and haematopoietic origin express CXCR4 (REF. 8).Not all cancerous cells in the primary 
tumour are CXCR4 positive. In ovarian and non-small-cell lung cancer, for instance, only a 
sub-population of cells expresses this receptor  [57]. When it has been possible to study 
freshly isolated tumour cells — for example from leukaemias and cells that have been 
isolated from ovarian cancer ascites — the CXCR4 receptor is functional and various 
signalling pathways are activated. 
CXCR4 is a member of the surface G protein–coupled seven-span transmembrane 
receptor class (Figure 5) that is expressed constitutively in a wide variety of normal 
tissues, including lymphatic tissues, thymus, brain, spleen, stomach, and small intestine 
[58]. This receptor is also expressed in normal stem cells from a variety of tissues, 
including mammary stem cells [59]. The fact that CXCR4 is present in normal mammary 
stem cells suggests that this molecule may be essential for stem cells that appear to be 
progenitors of  carcinoma [60]. Signaling through CXCR4 activates a number of 
downstream effector molecules, including molecules that regulate key processes such as 
cell cycle control and apoptosis. The homeostatic chemokine stromal cell-derived factor-1 
(CXCL12/SDF-1) is also expressed constitutively in a variety of tissues, including lung, 
liver, lymph nodes, bone marrow, and adrenal glands [20,58,61]. CXCL12 is highly 
20 
 
conserved between mice and humans with only a single amino acid substitution between 
the two species. 
 
 
 
 
Figure 5 CXCR4 receptor structure model. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Two different isoforms of this chemokine have  been identified in humans, CXCL12α and 
β. These isoforms are identical except for an additional four amino acids on the carboxyl 
terminus of CXCL12β. CXCL12α and β do not appear to differ in their functions as ligands 
for CXCR4, based on structure–function studies showing that the amino terminal region of 
CXCL12 is critical for activating the receptor [62]. CXCL12 binds to heparin and heparin 
sulfate glycosaminoglycans on the surfaces of cells and in the extracellular matrix, thereby 
increasing local concentrations of ligand to activate CXCR4 [63].The chemokine CXCL12 
regulates many essential biological processes, including cardiac and neuronal 
development, stem cell motility, neovascularisation and tumorigenesis [64-68].  
Besides the well known role of CXCR4 as a cofactor for human immunodeficiency virus 
infection of T lymphocytes [69], binding of CXCL12 to CXCR4 activates a variety of 
intracellular signal transduction pathways and effector molecules that regulate cell survival, 
proliferation, chemotaxis, migration, and adhesion. Briefly, the CXCL12/ SDF-1 – CXCR4 
axis promotes angiogenesis and the migration of tumor cells into the metastatic sites in 
many cancers, like breast [20, 70], lung [61], ovarian [71], renal [72], prostate [73] cancer, 
and neuroblastoma [74]. These CXCR4 expressing tumors preferentially spread to tissues 
that highly express CXCL12/SDF-1, including lung, liver, lymph nodes and bone marrow. 
The involvement of this receptor–ligand interaction in the directed migration of cancer cells 
to metastatic sites has been reviewed by Balkwill [22].  
The large number of downstream effector molecules regulated by CXCR4 likely account 
for the multiple effects of this receptor in the pathobiology of  cancer. The extent to which 
various molecules activated by CXCR4 relate to specific functions, such as proliferation 
and chemoinvasion, remains to be established clearly. The roles of various effectors of 
CXCR4 at defined stages in primary and metastatic breast cancer also have not been well 
established. Defining downstream effectors of CXCR4 in vivo is important to establishing 
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molecular mechanisms through which CXCR4 promotes cancer. Moreover, identifying key 
mediators of CXCR4 function in cancer is expected to enable rational selection of other 
therapeutic agents for potential use with new compounds targeted against CXCR4. 
CXCL12 and CXCR4 stimulate the phosphatidylinositol- 3-kinase pathway that 
subsequently activates the protein kinase AKT [75-77]. Activated AKT phosphorylates a 
wide variety of intracellular targets, functioning to inhibit apoptosis and prolong cell survival 
in many different types of cancer cells [78]. Beyond functions in promoting cell survival, 
AKT also has been implicated in effects of CXCR4 on proliferation of cells [76] and 
migration toward a chemotactic gradient of CXCL12 [79, 80]. 
The mitogen-activated protein kinase pathway (MAP kinase pathway) is another signal 
transduction pathway regulated by CXCR4. In response to CXCL12, CXCR4 activates the 
kinase MEK, the upstream activator of the p42/44 MAP kinases (also known as ERK 1/2). 
Because p42/44 activate the same downstream signal transduction pathway, these two 
related kinases generally are referred to as a single effector. Activated p42/44 MAP 
kinases phosphorylate transcription factors including Elk-1 to increase expression of genes 
that promote proliferation and survival of cancer cells (reviewed in [81, 82]. CXCR4 
activates several different intracellular events such as chemotaxis, invasion, and adhesion, 
all of which are properties that correlate with metastatic behavior of cancer cells in vivo. 
CXCL12 binding to CXCR4 promotes polymerization of actin to promote cell motility. 
CXCR4 also activates members of the src family of protein tyrosine kinases, thereby 
producing phosphorylation and activation of components of focal adhesion complexes 
such as RAFTK/Pyk2, focal adhesion kinase, Crk, and paxillin [83]. CXCR4 also promotes 
adhesion to components of the extracellular matrix, including collagen and fibronectin, 
through integrins a2, a4, a5, and b1 [84]. Focal adhesion complexes and integrins have 
been shown to promote migration of cells and interactions with extracellular matrix 
molecules. 
An important mechanism that alters the metastatic behavior of tumor cells in vivo is 
hypoxia. As the oxygen concentration decreases within a tumor, metastasis is favored, 
because hypoxia up-regulates CXCR4 in tumor cells via the hypoxia-inducible factor-1a 
(HIF-1a) [85, 86]. Hypoxic conditions in the tumor cell mass promote the transcription and 
translation of HIF-1a, whereas under physiological conditions, the tumor suppressor 
protein von Hippel– Lindau negatively regulates CXCR4 expression by the degradation of 
HIF-1a [87]. 
Further, CXCL12/SDF-1 is also involved in the invasion of tumor cells. Indeed, 
CXCL12/SDF-1 directed invasion of human basal carcinoma cells is mediated by the up-
regulation of MMP-13 [88]. MMPs play an important role in the invasion process because 
their proteolytic activities assist in the degradation of the extracellular matrix and basement 
membranes and are essential in order to promote intravasation of cancer cells from the 
primary tumor into blood vessels and extravasation at sites of metastases [83]. In addition, 
Pro-angiogenic effects of CXCR4 signaling may be mediated through upregulation of 
vascular endothelial growth factor (VEGF), an established pro-angiogenic molecule [89]. 
VEGF itself has been shown to increase expression of CXCR4 in breast cancer cells, 
thereby forming a potential positive feedback loop for promoting angiogenesis [90]. 
Therefore, these data suggest that another potential function of CXCL12– CXCR4 
signaling in cancer may be to directly or indirectly promote angiogenesis in primary and 
metastatic breast cancer. 
Interruption of the interaction between CXCL12/SDF-1 and its receptor may inhibit the 
metastatic process. Therefore, the CXCR4 receptor could be an important therapeutic 
target for cancer treatment. 
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1.3 Structure of SDF-1 and hypothesized molecular mechanism of its interaction 
with CXCR4 receptor 
 
The solution structure of SDF-1 provides the basis for addressing the structural features 
which are essential for function. Many aspects of the molecular biology and physiology of 
SDF-1 are unique, so we cannot assume that rules established for other chemokines 
apply. 
The structure of SDF-1 is well defined except for the N- and C-terminal residues, 1–8 and 
66–67, respectively. SDF-1 adopts a chemokine-like fold consisting of three anti-parallel β-
strands and an overlying α-helix (Figure 6). The well ordered regions include an extended 
loop (Arg12 to Ala19) which leads into a 310 helix (Arg20 to Val23). The first β-strand (24 
to 30) is connected by a type III turn (31 to 34) to the second β-strand (37 to 42) and the 
second and third β-strands (47 to 51) are connected by a type I turn (43 to 46). A type I 
turn (52 to 55) connects the third β-strand and the C-terminal α-helix (58 to 65) (Figure 
7A).. SDF-1β, was also characterized by NMR and the data indicated that like SDF-1 it is 
well defined between residues 9 and 65. There was no significant change in either 
secondary or tertiary structure as a consequence of the five residue C-terminal extension 
that distinguishes SDF-1βfrom SDF-1. 
 
 
 
 
 
 
 
Figure 6. Crystallographic 
structure of the chemokine 
CXCL12     
 
 
Chemokine structures that have been solved to date have a common tertiary fold that 
consists of an N-terminal region, a loop region that follows the CXC or CC motif, three 
antiparallel b-strands in a Greek key like arrangement, and a C-terminal a-helix. Several 
structural features are unique to SDF-1 and distinguish it from other chemokines (Figure 
7). Differences are apparent in the packing of the hydrophobic core and this is evident 
when we consider Trp57 which is highly conserved among CC chemokines and also 
present in IL-8. In SDF-1, Trp57 makes extensive NOE contacts with residues of the 310 
helix (Arg20, Val23), the first b-strand (Leu26), and the N-terminal loop (Val18). In 
contrast, in other chemokines, Trp57 is oriented away from the first β-strand and is packed 
predominantly against the side chains of residues in the N-terminal loop (Figure 7A). 
These differences in the hydrophobic core are reflected in the relative orientation of the α-
helix to the rest of the protein: in SDF-1 it is aligned more parallel to the β-strands, 
whereas in all other chemokines it is orthogonal to the β-strands (Figure 7B, C and D). 
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Figure 7 Comparison of 
SDF-1 with other 
chemokines. Ribbon 
outlines of: (A) SDF-1; (B) 
IL-8 (C) RANTES [91]and 
(D) GRO [92] Trp57 and 
the residue that 
corresponds to Leu26 of 
SDF-1 are shown in white 
to indicate the difference 
in their relative positions. 
Residues 1 to 8 in SDF-1, 
1 to 3 in IL-8, 1 to 7 in 
RANTES and 1 to 5 in 
GRO, are not shown for 
clarity. 
 
 
The packing requirements of the helix in SDF-1 are fulfilled by Trp57, Tyr61 and Leu62, 
which interact with residues of the first and second β-strands. Packing of the hydrophobic 
side chain of Leu55, which is part of the turn preceding the α-helix in SDF-1, also 
influences the hydrophobic core and the orientation of the helix. 
SDF-1 is a highly basic protein with 21% of the total residues being arginine, lysine or 
histidine. Analysis of the electrostatic potential at the molecular surface revealed further 
differences between SDF-1 and other chemokines. In SDF-1, positive surface charges are 
clustered along the first and second β-strands and the α-helix displays a predominantly 
negative surface charge. With CXC chemokines, a positively charged surface is clustered 
in the C-terminal α-helix, whereas the CC chemokines show no obvious pattern in the 
clustering of charges. The positive surface charge in IL-8 has been proposed to be critical 
for heparin binding [93]. SDF-1 has been shown to bind heparin with higher affinity than 
either IL-8 or MCP-1 [94], suggesting that the surface charge distribution of SDF-1 could 
provide an optimal binding site for heparin or other cell-surface glycosaminoglycans.  
To determine the SDF-1structural requirements for its biological function, a set of SDF-1 
analogs have been synthesized and assayed for their ability to bind CXCR4 and to induce 
functional activation of the receptor by measuring induction of intracellular calcium levels 
[62]. These analogs consist in N-terminal truncations, single substitution analogs and 
chimeras of SDF-1 with other CXC chemokines. 
 Based on these results Crump  proposed a two site model for SDF-1 binding to CXCR4 
(Figure 8).  
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Figure 8 A model for interaction of SDF-1 with CXCR4. A schematic depicting the interaction of SDF-1 with 
the receptor is shown.  (A) indicates the receptor and ligand separately. (B) indicates interaction of the SDF-
1 RFFESH loop (site 1) with the N-terminal segment of the receptor. The contact region is shown in blue. 
Two (C) Shows the N-terminal region (site 2) of SDF-1 bound in groove at the top of the helices (orange). 
Binding of the N-terminal region results in activation of the receptor, which is depicted in (C) by the change in 
conformation of the receptor helices compared with (B). 
 
The two receptor binding sites are contained in SDF-1 (1–17) that has the sequence: 
KPVSLSYR-CPC-RFFESH. The results show that the RFFESH site is important for 
optimal binding, but is not sufficient for receptor activation, and this region (site 1) makes 
the initial contact with the receptor (A to B). 
In fact this step serves as an initial SDF-1 docking step, and this step could be like a key 
that permits access to the more buried receptor site. In the subsequent step (B to C), the 
N-terminal residues bind to a groove amongst the helices, which induces a change in the 
conformation of the receptor transmembrane helices that allows intracellular G-protein 
binding and signaling of cellular function [95]. The N-terminal region (site 2), which is 
disordered in solution, becomes structured during binding and establishes contacts with 
the receptor groove. Nevertheless, addition of a Gly residue to SDF-1 did not affect activity 
and some of the N-terminal residues could be modified with minimal change in function. 
This suggests that the bound form of the N-terminal region is not completely buried within 
the transmembrane region, but rather is bound in a shallow site. Receptor activation 
requires Lys-1 and Pro-2 within the N-terminal region. Modifications to Lys-1 and Pro-2 
result in antagonists because the variants can no longer induce the conformational change 
in the receptor that is required for activation.  
In conclusion, this hypothesized two-step mechanism for the interaction of SDF-1 with 
CXCR4 has provided the molecular basis for the design of SDF-1 analogs to be used as 
agonists or antagonists of the receptor target.  
 
 
1.4 CXCR4 antagonists: AMD3100 and T-140 
 
CXCR4 first drew attention as a major coreceptor for the infection of T cell line-tropic (X4) 
strains of human immunodeficiency virus 1 (HIV-1) [96, 97]. Interaction between the 
gp120/CD4 complex and a coreceptor, such as CXCR4 or CCR5, triggers conformational 
changes in the viral envelope (Env) that lead to membrane fusion and entry of the viral 
genome into the host cell cytoplasm (Figure 9) [98, 99]. 
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Figure 9 A model for the 
HIV-1 entry mechanism. 
 
 
 
 
 
 
 
 
 
 
 
Importantly, the CXCR4 receptor is expressed much more broadly than chemokine 
receptors in general, that is, not only on a wide variety of leukocytes but also on cells 
outside the immune system. Compelling evidence is accumulating that the CXCR4 is far 
more than a coreceptor for HIV, playing an important role in cancer metastasis, regulation 
of stem cell trafficking, and neovascularization [100-103]. Consequently, therapeutic 
strategies to block the interaction between CXCR4 and SDF-1 hold promise for a variety of 
clinical applications. Since the identification of human immunodeficiency virus (HIV) as the 
causative agent of the acquired immune deficiency syndrome (AIDS) and the disclosure of 
CXCR4 as a coreceptor for HIV entry, various peptide CXCR4 antagonists, such as T140 
and low molecular weight pseudopeptide CXCR4 antagonists, have been reported [104-
108]. They have been proven to be efficient agents against HIV infection, as well as 
cancer metastasis, leukemia and rheumatoid arthritis.  The bicyclam AMD3100 (plerixafor) 
is a nonpeptidic synthetic inhibitor of the CXCR4 receptor. Originally discovered as a 
potent and selective anti-HIV agent,  it was found to be a strong inducer of "mobilization" 
of hematopoietic stem cells from the bone marrow to the bloodstream as peripheral blood 
stem cells [109]. Moreover, Plerixafor was seen to decrease metastasis in mice in several 
studies [70]  and to decrease recurrence of glioblastoma in a mouse model after 
radiotherapy [110]. 
 
 
1.4.1 AMD3100 
 
AMD3100 is composed of two 1,4,8,11-tetraazacyclotetradecane (cyclam) moieties 
connected by a conformationally constraining heteroaromatic phenylenebismethylene 
linker (Figure 10). 
 
 
 
  Figure 10 Structure formula of CXCR4 best known antagonist: 
AMD 3100. 
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AMD3100 is highly specific for CXCR4 and inhibits the binding and function of CXCL12 
and the HIV cell entry with high affinity and potency [111, 112] through an electrostatic 
interaction with three acidic residues, Asp171 (AspIV:20), Asp262 (AspVI:23), and Glu288 
(GluVII:06) located in the main ligand binding pocket of CXCR4 [113-115] (Figure 11). In 
more details, it has been supposed that one cyclam ring of AMD3100 interacts with 
Asp171 in TM-IV, whereas the other ring is sandwiched between the carboxylic acid 
groups of Asp262 and Glu288 from TM-VI and -VII, respectively [114]. Importantly, the 
high potency and efficacy of AMD3100 requires the presence of a rigid linker between the 
two cyclam moieties [113]. Previously described monocyclams as well as bicyclams with 
flexible linkers that were less potent were shown only to be dependent upon AspIV:20 
[113]. 
AMD3100 binds with extreme specificity to CXCR4, independently of the cell type that 
carries this receptor: as monitored by chemokine-induced signalling, AMD3100 does not 
interact with a variety of chemokine receptors other than CXCR4, namely CXCR1–3 and 
CCR1–9 [116].  This prompts the prediction that AMD3100 would interfere with a number 
of pathophysiological processes mediated by CXCR4 but not any of the other CXCR or 
CCR receptors. 
Gupta et all. have studied CXCR4 – AMD3100 interaction by evaluating inhibition of SDF-
1α  induced chemotaxis and Ca+2 flux inHL-60 cells and by evaluating the effect of 
AMD3100 on SDF-1α  binding with CXCR4 in a radioligand binding assay [117]. Although, 
AMD3100 competed with [125I]-SDF-1α for its CXCR4-specific binding in a dose dependent 
manner, significantly, its IC50 in the radioligand binding assay was upto 3000-fold less 
potent (15.2 µM vs 4.7 nM) as compared with its effect in the functional assays.  
 
 
 
 
 
 
 
 
 
 
 
Figure 11 Serpentine and helical 
wheel diagram of the CXCR4 
receptor. Yellow background 
indicates previously identified ―hits‖ 
for the interaction of AMD3100 with 
CXCR4 [113, 114]. 
 
 
 
 
 
 
 
 
 
Taken together, these results reveal an apparent discrepancy between the effect of 
AMD3100-mediated functional antagonism versus radioligand binding. This discrepancy is 
best explained by invoking a two-site model for SDF-1-CXCR4 interaction [62] 
characterized byan initial docking step the N-terminal region of CXCR4 interacts with the 
R-F-F-E-S-H motif of SDF-1 (Figure 12A, B). and subsequent interaction of CXCR4 with 
the N-terminal residues (aa 1–11) of SDF-1 (K-P-V-S-L-S-Y-R-CPC-), thus triggering its 
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functional response (Figure 12C). Hence, in this two-site model, a receptor-specific 
CXCR4 antagonist like AMD3100 may be a potent functional antagonist by virtue of 
perturbing ligand interaction at one site, but without a concomitant effect on ligand 
displacement in a radioligand binding assay (Figure 12D). 
 
 
Figure 12 Pharmacological evidence 
for the schematic model from Crump 
et al. [62], depicting interaction of 
SDF-1 with CXCR4. (A) and (B) The 
intital docking step occurs between 
the N-terminal residues of CXCR4 
and the R-F-F-E-S-H motif of SDF-1. 
(C) Conformational changes lead 
to interaction of the extracellular 
loops of CXCR4 with aa 1–11 of 
SDF-1. (D) Interaction of a small 
molecule antagonist like AMD3100 
inhibits functional signal transduction 
without displacement of radiolabeled 
SDF-1. 
 
 
 
Despite the fact that AMD3100 is a highly potent and specific CXCR4 antagonist, it does 
not exhibit oral bioavailability presumably due to the positive charge (+2) of each ring at 
physiological pH [118-120].  Long term treatment in HIV-infected persons may therefore be 
difficult. However, subcutaneous administration in combination with granulocyte-colony 
stimulating factor improves stem cell mobilization yields in patients undergoing 
transplantation [121]. 
In a recent study has been characterized the molecular mechanism of action of a novel 
series of monocyclam CXCR4 antagonists designed from the prototype symmetrical 
bicyclam AMD3100 (Figure 13).  
 
 
 
 
 
 
Figure 13 Different 
monocyclams, AMD3465, 
AMD3529 and AMD3389 
direved from the bicyclam 
AMD3100.  
 
 
 
 
 
 
 
In these compounds one of the cyclam rings was substituted with aromatic phenyl or 
pyridine rings (the ―non-cyclam part‖) linked by an N-substituted aliphatic chain and the 
original phenylenebismethylene linker to the remaining cyclam ring (i.e. the ―cyclam part‖). 
The binding of such analogs as well as its antagonistic properties was describe in respect 
of blocking CXCL12-induced activation and HIV cell entry. AMD3465, in which one of the 
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fournitrogen cyclam moieties has been replaced by a two-nitrogen N pyridinylmethylene 
moiety, binds with higher affinity and inhibits the CXCR4 signaling with higher potency 
than the classic, symmetrical bicyclam antagonist AMD3100. The low affinity of AMD3529 
and AMD3389 (as compared with AMD3100 and AMD3465) indicates that the pyridine 
interaction of AMD3465 with the III-VI-VII pocket is necessary for high-affinity interaction 
with CXCR4. These interaction studies indicate that the pyridine ring of AMD3465 is 
interacting mainly with AspVI:23 and HisVII:-02 in a mode that cannot be mimicked by the 
corresponding phenyl group of AMD3529 (Figure 14). 
 
 
 
Figure 14 Residues identified 
through mutagenesis to be 
important for the binding of 
AMD3100 and AMD3465 shown in a 
helical wheel diagram of the CXCR4 
receptor. The background color 
indicates the magnitude of the effect 
of the mutation on the binding of 
eitherAMD3100 (left panel) or 
AMD3465 (right panel). Gray 
background indicates <10-fold 
decrease in affinity; yellow, 10–50-fold 
decrease; orange, 50–500-fold 
decrease; and red, >500-fold 
decrease in affinity. 
 
 
 
 
1.4.2 T140 
 
Self-defense peptides with antibacterial and antiviral activities, tachyplesins and 
polyphemusins, have been isolated from the hemocyte debris of the Japanese horseshoe 
crab (Tachypleus tridentatus) and the American horseshoe crab (Limulus polyphemus), 
which are 17-mer and 18-mer peptides, respectively (Figure 15) [122, 123]. Preliminary 
structure-activity relationship studies of these peptides have led to the development of T22 
([Tyr5,12, Lys7]-polyphemusin II) [124, 125].  and its downsized 14-mer peptide, T140, 
which possess strong anti-HIV activity (Figure 15) [126].  T22 and T140 effectively block 
X4-HIV-1 entry into cells by binding specifically to CXCR4, and inhibit Ca2+ mobilization 
caused by CXCL12 stimulation against CXCR4 [127-129].  In addition, a T140 analog 
exhibited a remarkable and significant delaying of the appearance of drug resistant strains 
of HIV in passage experiments using cell cultures in vitro [130], and it was presumed that 
the T140 analogs would be useful for its suppressive effect against drug resistant strains. 
 Structural analysis revealed that T140 forms an antiparallel β-sheet structure supported 
by a disulfide bridge between Cys4 and Cys13, which is connected by a type II‘ β-turn 
[131]. Four amino acid residues that were contained in T140, Arg2, L-3- (2-
naphthyl)alanine (Nal)3, Tyr5 and Arg14, were identified as residues indispensable for 
significant activity [132].  
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Tachyplesin I
Polyphemusin II
increase in anti-HIV activity
T22
T140 H-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-D-Lys-Pro-Tyr-Arg-Cit-Cys-Arg-OH
downsizing
increase in anti HIVactivity and biostability
4F-benzoyl-TN 14003 4-Fluorobenzoyl-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-D-Lys-Pro-Tyr-Arg-Cit-Cys-Arg-NH2
H-Lys-Trp-Cys-Phe-Arg-Val-Cys-Tyr-Arg-Gly-Ile-Cys-Tyr-Arg-Arg-Cys-Arg-NH2
H-Arg-Arg-Trp-Cys-Phe-Arg-Val-Cys-Tyr-Lys-Gly-Phe-Cys-Tyr-Arg-Lys-Cys-Arg-NH2
H-Arg-Arg-Trp-Cys-Tyr-Arg-Lys-Cys-Tyr-Lys-Gly-Tyr-Cys-Tyr-Arg-Lys-Cys-Arg-NH2
4F-benzoyl-TN 14011 4-Fluorobenzoyl-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-D-Glu-Pro-Tyr-Arg-Cit-Cys-Arg-NH2
= indispensable residues or pharmacophore 
moieties for CXCR4 antagonistic activity
Nal = L-3-(2-naphthyl)alanine
Cit = L-citrulline  
 
 
Figure 15 Structures of tachyplesin I, polyphemusin II, its analog T22, its downsized analog T140, its 
biostable analogs 4F-benzoyl-TN14003 and 4F-benzoyl-TE14011. 
 
However, T140 is proven to be biologically unstable, and biodegradable in mouse/feline 
serum or in rat liver homogenate [133, 134].  When indispensable amino acid residues 
(Arg14 in serum; Arg2, Nal3 and Arg14 in liver homogenate) are deleted from the N- and 
the C-termini, the efficacy of degraded peptides is dramatically reduced.  
Modification of T140 analogs at both termini efficiently suppresses the above 
biodegradations and leads to development of novel and effective compounds that show 
highly CXCR4-antagonistic activity as well as increased biological stability. Further studies 
on the N-terminal modifycation found an electron-deficient aromatic ring such as a 4-
fluorobenzoyl moiety at the N-terminus to constitute a novel pharmacophore for strong 
anti-HIV activity. The T140 analogs, which contain an N-terminal 4-fluorobenzoyl moiety, 
4F-benzoyl-TN14003 and 4F-benzoyl-TE14011, have anti-HIV activity two orders of 
magnitude higher than that of T140 and enhanced biostability in serum/ liver homogenates 
(Figure 15).  
Arg2, Nal3, Tyr5 and Arg14 of T140, which are located in close proximity to each other in 
space, are indispensable to high antagonistic activity against CXCR4 as described above. 
For downsizing of T140 analogs, a pharmacophore-guided approach was performed using 
cyclic pentapeptide libraries, which were composed of two L/D-Arg, L/D-Nal and L/D-Tyr in 
addition to Gly as a spacer. This approach led to FC131 [cyclo( Arg1-Arg2-Nal3-Gly4-D-
Tyr5-)], which showed strong CXCR4-antagonistic activity comparable to that of T140 
(Figure 16) [135].  Structural analysis of FC131 by NMR and simulated annealing 
molecular dynamics revealed the near symmetrical pentagonal backbone structure. 
A 4-fluorophenyl moiety found as a pharmacophoric moiety as described above was 
introduced into cyclic pentapeptides. Since replacement of the phenol group of D-Tyr5 by 
a 4-fluorophenyl group did not cause the maintenance of high potency, the 4-fluorophenyl 
group was incorporated into position 1. The resulting compound, FC401 ([Phe(4-F)1]-
FC131), shows significant CXCR4-binding activity (Figure 16) [136]. Next, since a second 
Arg residue is thought to be indispensable for high potency and an aromatic residue [L/D-
Phe(4-F)] has been incorporated into position 1, four analogs [L/D-Phe(4-F)1, L/D-Arg5]-
FC131 were synthesized based on replacement of D-Tyr5 by L/D-Arg5. 
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Among these analogs, FC602, which is [D-Phe(4-F)1, Arg5]-FC131, shows the most 
potent activity, which is 10-fold greater than that of [D-Tyr1, Arg5]-FC131 (Figure 16). 
Thus, FC602 is a novel lead, which involves a pharmacophore moiety different from the 
pharmacophore groups of FC131. 
 
 
 
 
 
 
 
 
Figure 16 Structures of 
cyclic pentapetides FC131, 
FC401 and FC602. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Identification of a novel pharmacophore for CXCR4 antagonism, such as a 4 fluorobenzoyl 
or 4-fluorophenyl moiety, led to develop a linear type of low molecular weight CXCR4 
antagonists. By combining substructure units of the T140 pharmacophore and new 
pharmacophore moieties, several compounds were designed and synthesized using 
combinatorial chemistry. As a result, several linear compounds were found as moderate 
CXCR4 antagonists, such as compounds 1–3 shown in Figure 17 [137].  These 
compounds are relatively weaker than a cyclic pentapeptide FC131. Thus, it is thought that 
conformational constriction based on a cyclic pentapeptide scaffold is critical for strong 
potency. Anthracene derivatives possessing two sets of zinc(II)-2,2‘-dipicolylamine 
complex were previously found as useful chemosensors that can selectively bind to 
phosphorylated peptide surfaces [138]. Several low molecular weight compounds bearing 
the complex structure were identified as selective CXCR4 antagonists [139]. Molecular 
superposition of structures of the zinc(II)-2,2‘-dipicolylamine complex compound 4 and the 
cyclic pentapeptide FC131 was investigated as it provided the best fit with the 
maintenance of local energy minimizations of both of the structures (Figure 17). The 
distance between two dipicolylamine moieties of compound 4 is estimated to be nearly 
equal to that between the two Arg side chains of FC131. Thus, the distance of these 
functional groups is thought to be essential for expression of CXCR4 antagonistic activity. 
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Figure 17 Structures of a 
linear type of low molecular 
weight CXCR4 antagonists 
 
 
 
 
 
 
 
 
1.5 Aims of the project 
 
The aim of this project is the design, synthesis and biological evaluation of new peptide 
analogues endowed with a good binding affinity toward the receptor CXCR4, in order to be 
used as therapeutic agents, if able to modulate the receptor target functional roles, or to be 
used as diagnostic markers.   
Due to their involvement in several fundamental steps of inflammation  and other immune 
response, as it was illustrated in the previous paragraph, chemokines in general represent 
an interesting target for many diagnostic or therapeutics approaches. However, the 
number of chemokines and of their different biological pathways requires considerable 
effort to correctly identify sequence or structure associated to different activities and 
responsible for observed specificities. To identify such relationships, we have been firstly 
focused on a compared analysis of sequences, whenever available, structures and, in 
particular, on locally conserved motifs, to be used both to verify hypothesized 
relationships, and as template to design and synthesize biologically active ligands of 
CXCR4 receptor. As next step, on the structural basis of the most active peptide 
sequence, we have developed new synthetic strategy  in solution and in solid phase in 
order to prepare modified amino acids  to be used as a building block in peptidomimetic 
synthesis. The final goal has been to  introduce conformational constraint into the peptide 
sequence by which it would be possible to stabilize the so-called 'bioactive' conformation, 
that is the peptide conformation required for receptor binding and activation. 
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2. Rational design and synthesis of peptide ligands 
 
2.1  Rational design 
 
In general, chemokine structures presently solved share a high homology, all exhibiting a 
central core of three β-strands, with an overlying C-terminal α-helix [62]. Other common 
features are a disordered N-terminus, the CXC or CC disulphide motif and and extended 
loop (termed N-loop), preceding the strand region.  
As for other chemokines, structure-activity studies of SDF-1 have shown the critical role of 
the N-terminal region for both receptor binding and activation and in particular the residues 
1-8 and 12-17, these last being located in the loop region [62]. vMIP-II, a CC chemokine-
like protein encoded by Kaposi's sarcoma-associated herpesvirus, binds and blocks 
chemokine receptors belonging to the CXC, CC and XC class, such as CCR1, CCR2. 
CCR5, CCR8, XCR1 and CXCR4 [140, 141]. As for SDF-1, the N-terminus and the N-loop 
are essential for receptor binding. In particular it was demonstrated that the N-terminus 
alone, encompassing residues 1-10, is sufficient for binding and antagonizing CXCR4 
receptor [142]. Therefore in this study we have focused on a sequence-structure 
comparison between the N-terminal regions of SDF-1 and vMIP-II, with the aim of looking 
for a possible common motif responsible for the binding to CXCR4. As three-dimensional 
structures of both SDF-1 protein and vMIP-II N-terminal region are available (PDB entries, 
2KED and 2FHT, respectively) a sequence-structure comparison between the N-terminal 
regions of the two proteins was performed, to look for a possible common motif 
responsible for their binding to CXCR4. Although a standard backbone superimposition 
shows apparently a local low sequence and structure similarity, the scenery changes 
dramatically when these regions are superimposed after reversing the direction of the 
backbone. In fact, this new comparison reveals a putative conserved motif, namely Ar-X-R 
(referred to vMIP-II backbone sense), where Ar1 is an aromatic residue and X is an 
aromatic or an unsaturated residue in which the orientation of the three sidechains is 
highly preserved. The sequence is R12-F-F14 for SDF-1 and W5-H-R7 for vMIP-II. In both 
cases the conformation of these stretches is well-ordered, falling in turn-like regions 
(Figure 18).  
 
 
 
 
 
 
Figure 18. Tridimensional 
structure of the conserved 
amminoacidic motif shared by 
SDF-1α (green) e vMIP-II 
(purple). 
 
 
 
 
 
 
 
In order to confirm this hypothesis, we designed, synthetized and tested a set of cyclic 
peptides enclosing this motif (Figure 19). The peptides differ in: a) nature of the aromatic 
residues or  residues with unsaturated ring; b) sequence sense (R-Ar1-X vs. X-Ar1-R); c) 
SDF-1, (1-17)
vMIP-II, (1-10)   LGAS            PDK
KPVSLSYR  CPC              ESHRFF
WHR
1 10 15
1 10
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N- and C-termination, as all combinations of free, single- and double-protected (by 
acetylation and amidation) termini were tested on selected peptides; d) possible elongation 
at either peptide termini by a Arg-Ala sequence. This latter sequence was tested to include 
another structurally-conserved basic residue (Arg8 in SDF-1, Lys11 in vMIP-II), potentially 
representing a further anchoring site to CXCR4 binding, Ala only acting as a spacer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19 Amino acid sequence of synthesized peptides divided into SDF-1 mimetic and vMIP-II mimetic. 
 
 
Peptides were designed with the following general scaffolds: (nf/nac)-C-Ar-X-R-C-(A-R-
cf/cf/cam) and (nf-R-A/nf/nac)-C-R-X-Ar-C-(cf/cam), where Ar represent aromatic residues, 
X represent aromatic residues or residues with an unsaturated ring , naf and nac are 
respectively free amino or acetyl group peptide N-terminations, cf and cam are free 
carboxylate or amide group C-terminations, slash-separated sequences in parenthesis 
represent alternative options, and underlining denotes the cyclic part of the peptides. For 
brevity, nf and cf terminations are omitted in the following sequence notations. The Ar1-X 
sequences occurring in biologically assayed peptides are WH, WY and FF, while peptides 
containing the WW sequence exhibited, in general, a too low solubility to be reliably 
assayed. Starting structures were obtained using the experimental SDF-1 backbone 
conformation for the R-Ar1-X motif and by mutating the preceding and following residues 
H-Cys-Trp-His-Arg-Cys-OH
H-Cys-Phe-Phe-Arg-Cys-OH 
H-Cys-Trp-Tyr-Arg-Cys-OH 
H-Cys-Trp-Trp-Arg-Cys-OH 
vMIP-II-mimetic (X-X-Arg) 
Ac-Cys-Trp-His-Arg-Cys-OH
Ac-Cys-Phe-Phe-Arg-Cys-OH
Ac-Cys-Trp-Tyr-Arg-Cys-OH
Ac-Cys-Trp-His-Arg-Cys-NH2
Ac-Cys-Phe-Phe-Arg-Cys-NH2
Ac-Cys-Trp-Tyr-Arg-Cys-NH2 
H-Cys-Trp-His-Arg-Cys-NH2
H-Cys-Phe-Phe-Arg-Cys-NH2
H-Cys-Trp-Tyr-Arg-Cys-NH2 
SDF-1α mimetic (Arg-X-X) 
H-Cys-Trp-His-Arg-Cys-Ala-Arg-OH 
H-Cys-Trp-Tyr-Arg-Cys-Ala-Arg-OH 
H-Cys-Phe-Phe-Arg-Cys-Ala-Arg-OH 
H-Arg-Ala-Cys-Arg-His-Trp-Cys-OH 
H-Arg-Ala-Cys-Arg-Phe-Phe-Cys-OH 
H-Arg-Ala-Cys-Arg-Tyr-Trp-Cys-OH 
SDF-1
vMIP-II
RFF
WHR
C16
C9
C3
C14
C2
C10
C1
C18
C17
C6
C4
C12
C5
C8
C18
C11 C13
C15
C7
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with cysteine residues, while the sense of peptide sequence was alternatively derived from 
vMIP-II or SDF-1. The choice of using SDF-1 backbone but with the sequence order of 
vMIP-II was guided by the better ring closure propensity of the former, combined to 
potentially antagonist behavior of the latter, inferred by the observed binding properties of 
vMIP-II N-terminal peptides [142]. The sequence reversal in RACRHWC (C16), 
RACRYWC (C17) and RACRFFC (C18) peptides was introduced to try to factorize the 
influence of sequence nature vs. sense on observed experimental properties. All peptides 
originate from the same scaffold with aromatic side chains mutated opportunely. Other 
than the natural sequences, also variant with Tyr and Trp residues at second position were 
designed to test the effect and the modularity of bulkiness and hydrogen bonding 
capability.  
5 ns molecular dynamics (MD) simulations in solution were carried out to evaluate the 
effects of cyclization mode, elongation and termination on both side chains orientation and 
backbone conformation of the putative motif. The most evident feature emerging from 
trajectory analysis, common to all simulated peptides, is the relatively high conformational 
stability during the 5ns simulated time, the r.m.s.d. of final snapshot from average structure 
calculated on backbone atoms for the four peptides variants, namely CWHRC (C1), 
CWYRC (C2) and CFFRC (C3) being .0.41, 0.30, 0.62 Å, respectively. The final peptide 
conformation well fit onto the experimental conformation of vMIP-II at level of both central 
core and side-chain spatial orientation. However, local conformational differences and, 
especially, presence of the cycle closure sequence, may affect the rotamer distribution of 
WHR sidechains, potentially altering the relative stability of the different substates 
observed during the simulation, in comparison with vMIP-II and SDF-1.  
The lack of direct information about the true bioactive conformations of our templates 
prevents any simple evaluation of these effects, but, as explained in the ―Discussion‖ 
section, further activity is planned to address this issue. 
Potentially destabilizing effects of partial or full protection at peptide termini were also 
investigated by MD simulations on CWHRC, but no appreciable modification on overall 
peptide conformation was observed, the r.m.s.d. respect to the average structure being 
less than 0.25 Å for all combinations of terminal protection. MD simulations carried out on 
CFFRCAR (C15) and RACRFFC (C18), selected as probe peptides to investigate the 
conformational propensities of seven residues peptides, showed an opposite behavior in 
H-bond capability both between each other and in comparison with their corresponding 
template proteins: in fact, only CFFRCAR (C15) is able to form a stable interaction 
between Arg4 side chain and the C-terminal oxygen atoms, that reproduces the H-bond 
between Arg12 side chain and the carbonylic oxygen of Cys9 in SDF-1 structure, even if 
its sequence order derives from vMIP-II, where such H-bond is absent. The substantial 
preservation of the relative sidechain orientation observed in template structures and the 
overall small conformational variations (compared to both linear and cyclic peptides of 
comparable size) during the MD simulations suggest a major role for this motif in the high 
structural stability experimentally observed for the vMIP-II(5-8) peptide [142].  In addition, 
the high conformational similarity shared by all simulated peptides suggests that most of 
the differences observed in biological properties among the peptides may be ascribed to 
local interactions of single atoms or groups with the receptor, rather than to intrinsic 
conformational preferences of each peptide. 
The main goal in the design of this new class of peptides with potential agonist/antagonist 
activity toward CXCR4 receptor was to test a hypothesis about the activity of a short motif, 
identified, in reversed sequence order, both in SDF-1 and in vMIP-II N-terminal regions.  
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2.2  Peptide synthesis 
A rational designed 18-membered library, consisting of different cyclic peptides, was 
synthesized on solid phase by using Fmoc chemistry standard protocols. Different solid 
supports were employed to construct the peptidic moieties. Rink Amide resin was 
employed as solid support to synthesize C7, C8, C9, C10, C11, and C12 (Figure 20) 
bearing an amido group at the C terminus, while Wang resin was employed to synthesize 
all the other linear compounds (Figure 21).  
 
 
Ac-Cys-Trp-His-Arg-Cys-OH
C 4
Ac-Cys-Trp-Tyr-Arg-Cys-OH
C 5 
Ac-Cys-Phe-Phe-Arg-Cys-OH
C 6
H-Cys-Trp-His-Arg-Cys-NH2
C 7 
H-Cys-Trp-Tyr-Arg-Cys-NH2
C 8
H-Cys-Phe-Phe-Arg-Cys-NH2
C 9 
Ac-Cys-Trp-His-Arg-Cys-NH2
C 10 
Ac-Cys-Trp-Tyr-Arg-Cys-NH2
C 11 
Ac-Cys-Phe-Phe-Arg-Cys-NH2
C 12 
a)
c)
b)
 
 
Figure 20 Amino acid sequence of synthesized peptides divided into: a) peptides acetylated at N-teminus; b) 
peptides with an amido group at the C-terminus and c) peptides acetylated at N-teminus and with an amido 
group at the C terminus. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21 Amino acid sequence of synthesized peptides with free C- and N-terminus. 
 
 
As shown in scheme 1, for all coupling reaction were used PyBop e HOBt as activating 
agents. N-terminal amino of peptide C4, C5, C6, C10, C11 and C12 (Figure 20) were 
acetylated on solid support with a mixture of 4.7% acetic anhydride  and 4% pyridine in 
H-Cys-Trp-His-Arg-Cys-OH  
C1
H-Cys-Trp-Tyr-Arg-Cys-OH
C2
H-Cys-Phe-Phe-Arg-Cys-OH
C3
H-Cys-Trp-His-Arg-Cys-Ala-Arg-OH
C13
H-Cys-Trp-Tyr-Arg-Cys-Ala-Arg-OH
C14
H-Cys-Phe-Phe-Arg-Cys-Ala-Arg-OH
C16C15
C14C17
H-Arg-Ala-Cys-Arg-His-Trp-Cys-OH
H-Arg-Ala-Cys-Arg-Tyr-Trp-Cys-OH H-Arg-Ala-Cys-Arg-Phe-Phe-Cys-OH
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DMF. The peptide cleavage from the solid support and the deprotection of all amino acid 
residues were obtained upon treatment with high percentage of trifluoroacetic acid, H2O 
and triisopropylsilane (TFA/H2O/EDT 94:4:2). The cyclisation reaction was performed by 
disulphide bridge formation between two cysteine residues. In particular the oxidation 
reaction was performed dissolving the crude products in aqueous solution (0.1 M) of 
NH4HCO3 . All compounds were obtained in good yield and with high purity grade (>95%) 
after RP-HPLC purification. They were fully characterized for their identity by mass 
spectrometry. 
 
 
 
 
Scheme 1 Peptide ligands synthetic strategy.  
 
 
 
 
 
 
 
O
OH
NHNleO
O
NHO
O
Fmoc
-Cys(Trt)-Arg(Pbf)-X-X-Cys(Trt)-Fmoc
[-X-X-Arg-]
(1) protected amino acid
PyBop/HOBt/DIPEA
(2) 20% piperidine in DMF
(1) 20% piperidine in DMF
(2) 3h, TFA/H2O/EDT
Y-Cys(Trt)-X-X-Arg(Pbf)-Cys(Trt)-OH
Y= H, NH2
(2) 4.7% Ac2O  and 4% 
pyridine in DMF
(1) 20% piperidine in DMF
(3) 3h, TFA/H2O/EDT
Ac-Cys(Trt)-X-X-Arg(Pbf)-Cys(Trt)-Z
Z= OH, NH2 H-Arg-Ala-Cys(Trt)-X-X-Arg(Pbf)-Cys(Trt)-OH
(1) Fmoc-Ala-OH; Fmoc-Arg(Pbf)-OH
PyBop/HOBt/DIPEA
(2) 20% piperidine in DMF
3) 3h, TFA/H2O/EDT
NH4HCO3 0.1 M
NH4HCO3 0.1 M
NH4HCO3 0.1 M
H-Cys-Trp-Tyr-Arg-Cys-NH2C8 :
H-Cys-Trp-Tyr-Arg-Cys-OHC 2 :
C 1 : H-Cys-Trp-His-Arg-Cys-OH
C 7 : H-Cys-Trp-His-Arg-Cys-NH2
C 9 : H-Cys-Phe-Phe-Arg-Cys-NH2
C 3 : H-Cys-Phe-Phe-Arg-Cys-OH
C 4 : Ac-Cys-Trp-His-Arg-Cys-OH
C 10 : Ac-Cys-Trp-His-Arg-Cys-NH2
C 6 : Ac-Cys-Phe-Phe-Arg-Cys-OH
C 5 : Ac-Cys-Trp-Tyr-Arg-Cys-OH
C 11 : Ac-Cys-Trp-Tyr-Arg-Cys-NH2
C 13 : H-Cys-Trp-His-Arg-Cys-Ala-Arg-OH
C 15 : H-Cys-Phe-Phe-Arg-Cys-Ala-Arg-OH
C 14 : H-Cys-Trp-Tyr-Arg-Cys-Ala-Arg-OH
C 16 : H-Arg-Ala-Cys-Arg-His-Trp-Cys-OH
C 17 : H-Arg-Ala-Cys-Arg-Tyr-Trp-Cys-OH
C 18 : H-Arg-Ala-Cys-Arg-Phe-Phe-Cys-OH
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3. Biological evaluation 
In order to evaluate the peptide ability to modulate CXCR4/SDF-1α axis activation and to 
understand singular event concerning receptor activation, different biological assays were 
performed.  
In particular peptides biological studies consist in evaluate: 
- Binding through flow cytometry 
- Modulation of  intracellular Ca2+ release. 
- Modulation of cell migration in presence or without specific ligand SDF-1 
- Modulation of P-Erk activation. 
In these studies two cellular lines were employed: CCRF-CEM, T-leukemia cell lines and 
PES43, human melanoma cell line.   
For In vivo studies B16 melanoma cells were engineered to express human CXCR4 and 
then were demonstrated striking lung metastases inhibition of mouse melanoma B16-
CXCR4 cells were inoculated into the tail vein of C57/BL mice. 
 
 
CXCR4 cyclic peptides impaired CXCR4 binding. 
 
The cyclic peptides binding to CXCR4 was evaluated through flow cytometry. Briefly, 
CCRF-CEM cells were incubated with the CXCR4 inhibitor, AMD3100 10 µM or the ligand 
peptides (10 µM for 30 minutes). In Figure 22 A, CXCR4 binding was impaired by the 
peptide C16 (10 µM) compared to AMD3100 10 µM. Figure 22B showed that the seven-
residue peptides with sequence derived from CXCL12 (C16, C17, C18) reduced the 
binding PE-CXCR4 antibody to the receptor (respectively 17, 22 and 21%); peptide C1 
also inhibited CXCR4 binding (55% versus 10-30% AMD3100). The interaction with the 
other peptides minimally affected the  binding. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22 Indirect CXCR4 binding: Assessment of Peptides binding to CXCR4. Experiments were 
conducted using CCRF–CEM cells. The amount of AMD3100/peptides bound was assessed indirectly by 
flow cytometry using the PE-labelled anti-CXCR4 antibody. A Example experiment, i) CNT VS MabCXCR4 ii) 
Mab CXCR4 VS AMD3100 10 μM iii) Mab CXCR4 VS Peptide C16 10μM;  B The results are expressed as 
the percent antibody bound in the presence of AMD3100/peptides; 
 
i) CNT VS MabCXCR4 ii) Mab CXCR4 VS 
AMD3100 10M
iii) Mab CXCR4 VS Peptide 
C16 10M
A
B
CNT AMD 
3100
C6 C12 C4 C10 C5 C11 C3 C9 C1 C7 C2 C8 C15 C13 C14 C18 C16 C17
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CXCR4 cyclic peptides inhibited calcium release CXCL12 induced.  
 
CCRF-CEM pretreated for 1 hour with 10 µM of ligand peptides, were loaded with Fluo-
3AM. In figure 23A the effect of peptide C17 was evaluated;  ionomicyn value being the 
positive control. As showed in Figure 23B peptide C17 (33.65%), C9 (49.1%), C16 
(49.75%), C18 (51.25%) and C10 (57.35%) clearly reduced the calcium efflux in 
comparison to the AMD3100 effect (32.85%). Other peptides have a moderately 
antagonist (>60) up to weakly agonist (<106) effect; peptide C5 (110.35%) and C4 
(125.25%) increasing calcium efflux. 
 
Ionomicyn
AMD3100
CXCL12
C17
a) b) 
c) d) 
A
B
CNT AMD 
3100
C6 C12 C4 C10 C5 C11 C3 C9 C1 C7 C2 C8 C15 C13 C14 C18 C16 C17
 
Figure 23 Calcium Efflux: Inibhition of SDF-1 medieted calcium efflux. The assay was performed using 
CCFR-CEM and Fluo-3 AM calcium indicator. CCFR-CEM were incubated 30'min. at 37°C with Fluo-3 AM 
and 15'min with AMD/peptides and then treathed with Ionomicyn/SDF-1 before get analyzed. A CEM treated 
with ionomicyn (a) rapresent the maximun calcium efflux; in b), c) and d) the misuration of CXCL12 mediated 
calcium efflux alone and in presence of AMD3100/C17 as example; B The result are expressed  as the 
percent of Fluo-3 AM fluorescence in presence of CXCL12 alone. 
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CXCR4 cyclic peptides inhibited P-Erk induction, cell migration and wound healing 
CXCL12 induced.  
 
To further evaluate the effect of cyclic peptides on CXCR4, P-Erk induction and migration 
CXCL12 induced were analyzed in PES43, human melanoma cells pretreated with the 
cyclic peptides. Briefly migration was conducted in 8 µm transwell. PES43, human 
melanoma cells [143] were seeded in the upper well and allowed to migrate toward FBS, 
BSA, CXCL12 (100ng/ml) in the presence of peptides. Migration index was defined as the 
number of cells migrating toward CXCL12. Figure 24A demonstrated an efficient inhibition 
of migration in the presence of  peptides C14, C18 and C17. Peptides C10, C1 and C16 
also reduced CXCL12-induced migration (50%). Interestingly, five peptides determined 
convincing migration increase. Peptides C7, C8, C11, C13 and C9 increased migration 
1.5-; 1.55-; 1.55-; 1.7- and 1.9-fold higher than CXCL12. 
Moreover wound healing assay was conducted in PES43 cells in the presence of CXCL12. 
Figure 24B shows the delay in wound healing in the presence of peptide C1, C16, C17 
and C18. Since functional CXCR4 transduce the signal activating P-Erk CXCL12 
dependent induction was evaluated in PES43 cells in the presence or absence of the 
CXCR4 cyclic peptides. In Figure 25A an example of P-Erk induction in the presence of 
peptides is shown. Peptide C18 reduced p-ERK-CXCL12-induced after 5 minutes 
compared to AMD3100 while it does not affect p-ERK in absence of CXCL12. In Figure 
25B  p-ERK modulation induced by cyclic peptides is shown. In particular peptides C1, C2, 
C18 and C16 clearly reduced p-ERK induction; peptides C12, C10, C11, C3 and C14 
demonstrated weak activity while peptides C6 and C17 did not interfere with P-ERK 
induction. Interestingly peptides C4, C5, C9, C7, C8, C15 and C13 showed increased p-
ERK induction. 
0h 6h
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Figure 24 Migration Assay: Migrated cells on the lower surface were fixed, stained with H&E and counted 
microscopically. In order to study the cell shape, cells were treated at 37°C with or without CXCL12 (100 
ng/ml) and AMD3100/peptides. A The results are expressed as the migration index respect to migration in 
presence of CXCL12 alone. B Delay in wound healing after 6 hours in presence of C1, C16, C17 and C18 
compared with CXCL12. Images were acquired with OKO Time Lapse. 
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Figure 25 P-ERK induction: CXCL12 induces phosphorylation of extracellular signal regulated kinases 
(ERK) 1 and 2 in PES43 cells. To study the inibition of CXCL12 mediated ERK phosphorylation in presence 
of AMD/peptides PES43 were serum-starved for 24 h and then incubated with CXCL12 (100 ng/ml) alone or 
in presence of AMD3100/peptides. Changes in the phosphorylation of p44/ 42 (Erk1/2) kinases were 
analysed by Western blotting using antibodies specific for the following proteins: phospho-ERK1 and 2, total 
ERK. A Example experiment. CXCL12 p-ERK induction was evaluated at 2, 5 and 20 minutes and was 
establish that the maximum is reached at 5 minutes. Peptide C18 inhibitory capability on p-ERK induction 
was at 5 minutes in presence and in absence of CXCL12. AMD3100 was used as negative control. B p-ERK 
induction evaluated in presence of inhibitory peptides plus CXCL12. 
 
 
CXCR4 inhibiting peptides C1, C18 and C16 inhibited melanoma metastases. 
 
The ―in vitro‖ screening of twenty CXCR4 cyclic peptides promoted to investigate in vivo 
activity of 3 selected peptides. To this aim B16 melanoma cells were engineered to 
express human CXCR4. Then 5x105 B16-CXCR4 cell, pre-incubated with AMD3100 (10 
µM) or peptide C1, C18 or C16 (10 µM) were inoculated into the tail vein of C57/BL mice. 
Mice were treated intraperitoneally once a day for 10 days (2 weeks) with 2mg/kg peptide 
C1, C18 and C16, 1.25mg/kg AMD3100 or PBS alone. Mice were euthanized after 4 
weeks and macroscopic inspection of lungs and H&E were performed. As showed in 
Figure 26 the lung derived from peptides  C1, C18 and C16 treatment  presented a 
dramatic decrease in metastases number compared to untreated mice. 
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Figure 26 Metastases Formation assay: We injected B16-CXCR4 tumor cells into the tail vein of 25 C57/B 
female mice and divided them in 5 groups with 5 mouse each goup: goup n°1 treated with PBS (b), and 
groups n° 2-3-4-5 treated rispectively with AMD3100 1.25mg/kg (c), C16 (c), C18 (d) and C1 (e). We injected 
2mg/kg of CXCR4 peptide antagonist for mouse 5 day weekly for 2 weeks i.p. We also have 1 mouse not 
injected as negative control. Tumor cells were 30' min pre-treated with antagonist and injected on the first 
day of treatment. Mouse injected with B16-CXCR4 cells and treated with control peptide developed big lung 
metastasis (4 animals on 5). On the other hand, animals treated with CXCR4 antagonist developed 
significantly fewer metastases or no metastasis. 
 
3.1  Discussion 
The role of CXCR4/SDF1 in tumour progression prompted to the discovery of CXCR4 
inhibitors. The best known CXCR4 antagonist is AMD3100, a bicyclam molecule initially 
used in the treatment of AIDS. Intratumoral AMD3100 inhibits the growth of glioblastoma, 
breast and prostatic cancers[22, 71, 77, 144-151]. Despite promising results AMD3100 
has considerable toxicity, mainly cardiac and is not orally bioavailable [119, 152]. Inibitory 
peptides were also described such as T22, T140 and TN14003 [52, 131, 132, 153]. These 
peptides were synthesized by combinatorial synthesis where, given a model compound, 
the changes are randomly implemented. More recently aimed at an antagonist with  
molecular-size smaller than T140 led to discovery CXCR4 antagonist with a cyclic 
pentapeptide template, FC131 with an high HIV-entry inhibition capability [137].  
The aim was to identify CXCR4-antagonist clinically suitable. The RFFESH CXCL12‘s 
domain was the starting point. In detail, a common structural domain was identified 
between CXCL12 N-terminal region and vMIP-II N terminal domain and a new library of 
cyclic peptide molecules was generated and tested through in vitro assays.  
The main goal in the design of this new class of peptides with potential agonist/antagonist 
activity toward CXCR4 receptor was to test a hypothesis about the activity of a short motif, 
identified, in reversed sequence order, both in SDF-1 and in vMIP-II N-terminal regions. In 
this view, the design was successful, producing peptides endowed with biological activity 
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in several assays addressing some of the many physiological and pathological functions of 
CXCR4 receptor.  
The biological assays on synthesized peptides revealed an unusual behavior of both the 
single peptides in different assays, and of the whole set of peptides in each assay. In 
addition, dramatic and non-additive effects of terminal protective groups were also 
observed. 
Looking at each assay in more detail, Q-Brite results show some degree of regularity, as 
seven-residue peptides with sequence order derived from SDF-1 (C16, C17 and C18) all 
exhibited substantially lower values (respectively 17, 22 and 21, comparable to the 10-30 
measured for AMD3100) than all other peptides, ranging from 60 to 90, with the only 
partial exception of C1, which scored an intermediate value of 45. 
Also in migration assay, the strongest inhibitory effect was observed for two of the seven-
residue peptides more active in Q-Brite test, namely C17 and C18, which exhibited the 
same 0.20 value measured for AMD3100, a strong antagonist activity being also 
associated to C14 (0.40). Other tested peptides exhibited behaviors varying from 
moderately antagonist, to weakly agonist. However, five peptides exhibited strong agonist 
behavior, with migration values equal or higher than 1.5 (the value measured for SDF-1): 
C7 (1.5), C8 (1.55), C11 (1.55), C13 (1.7) and C9 (1.9). 
A similar variance is also observed in calcium flux experiments, where C10  exhibited the 
strongest antagonism (40.7 vs. 32.85 measured for AMD3100), followed by C3 (53.3),  
C17 (56.0) and C9 (59.9). Other peptides have a moderately antagonist (>60) up to weakly 
agonist (<106) behavior, with two peptides, C5 (113.7) and C4 (121.4) showing strong 
agonism in this assay. 
An even more complex response was obtained in compared P.ERK assays in presence 
and absence of SDF-1. In fact, while some peptides exhibited values apparently 
compatible with either strong antagonism (C1, C9), or strong agonism, (C4, C13, C5, C8, 
C11 and C15) or strong partial agonism (C14, C3 and C15), or weak partial agonism (C2, 
C17 and C6), in one case (C12) the peptides in the absence of SDF-1 behaves as an 
agonist with the same value measured for SDF-1, thus making ambiguous any 
interpretation of the value obtained in the presence of SDF-1. However, the most striking 
results are obtained for C10 and C16, where an apparently weak to medium agonist 
behavior in the absence of SDF-1 turn into strong antagonism in the presence of SDF-1, 
and C7, for which an apparent synergy with SDF-1 is observed. The peptides (C1, C16 
and C18) significantly inhibited melanoma metastases and preliminary results showed that 
renal cancer cells xenograft  SN12C-pEGFP was significantly reduced in growth in the 
presence of peptides C1, C16 and C18.  
The pattern of biological responses elicited by these peptides was, however, very various, 
the behavior varying from agonism to antagonism, to inactivity for a same compound in 
different tests, and, more intriguingly, showing hints of non-additivity for their interaction 
with CXCR4 receptor in the presence of SDF-1. These results can not be explained by 
simple models for receptor activation/inhibition and suggest more complex interpretations, 
possibly involving direct SDF-1-peptide interactions and/or influence on symmetry, 
stoichiometry or structural variations of the homo- or hetero-oligomeric state of CXCR4 
receptor. These features, while prompting for new studies aimed at unraveling such a 
complex plot, open new perspectives in obtaining more selective compounds toward 
different biological pathways involving CXCR4 receptor. 
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4. Synthesis of peptide-chelating agent conjugates 
 
Small radiolabelled compounds such as peptides are very attractive tools for the diagnosis 
of several different pathologies [154]. With this idea in our mind, as a subsequent step, it 
was evaluated the possibility to develop peptide C18 derivative bearing a chelating agent 
able to coordinate radioactive metals for applications in cancer diagnosis by nuclear 
medicine techniques. In order to investigate the chelating agent site of linkage which does 
not interfere on the peptide-receptor interaction, two diethylentriaminopentacetic acid 
(DTPA)-C18 conjugates were synthesized:  one carrying DTPA moiety covalently bound to 
petide N-terminus (C20) and one carrying the chelating moiety DTPA covalently bound to 
the ε-NH2 of a lysine residue which replaced  Ala2 of C18 (C19).  
The DTPA chelating agent is routinely used to give in vitro and in vivo stable complexes of 
the radioactive isotope 111In(III). 
Scheme 2 shows synthetic process in order to obtain the compound C19 and C20 in good 
yield and with high purity. For compound C20, the DTPA(OtBu)4 was coupled, through its 
free carboxyl function, to the α-NH2 of the Arg  residue, after the last Fmoc deprotection 
step. This coupling step was performed using 2.0 equiv. of DTPA(OtBu)4 and HATU, and 4 
equiv. of DIPEA (DMF was used as solvent). The coupling time, compared with the 
classical solid phase peptide synthesis protocol, was increased to 2 h and completion of 
the reaction was checked by Kaiser test [155]. The conjugate cleavage from the solid 
support, the deprotection of all amino acid residues and cyclisation reaction were 
performed following the same protocol described in Peptide Synthesis paragraph.  
Concerning compound C19, after selective removal of the Metyltrityl group on the ε-NH2, 
the chelating agent DTPA(OtBu)4 was ancored to Lys2 side chain as described for C20. As 
final step, the N-terminal Fmoc was removed and the conjugate  obtained detached from 
the solid support and freed from its protective groups (see Peptide synthesis paragraph). 
The final cyclisation was performed as always described for each synthesized peptide. 
The successful synthesis of the two conjugates C19 and C20 allows the subsequent 
labelling of the peptide derivative with the radioactive isotope111In(III).  
Before performing nuclear medicine imaging studies, C19 and C20 were evaluated for 
their ability to inhibit the specific antibody binding  to CXCR4. As shown in Figure 27, both 
conjugates exhibited a reduced inhibiting activity, compared with that exerted by the only 
peptide sequence (C18). These results highlighted that the introduction of the chelating 
agent on the N-terminus, as well as on the lysine ε-NH2 group, can affect the binding 
process with the receptor target. We are currently exploring other peptide positions where 
to anchor the DTPA moiety. 
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Scheme 2 Synthetic strategy to obtain (DTPA)-C18 conjugates: C19, carrying the chelating moiety DTPA 
covalently bound to the ε-NH2 of a lysine residue and C20 carrying DTPA moiety covalently bound to petide 
N-terminus. 
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Figure 27 Indirect CXCR4 binding: Assessment of (DTPA)-C18 conjugates binding to CXCR4.  
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5. Peptidomimetics design 
 
Therapeutically relevant peptides themselves are seldom used in the clinic because of 
their poor biostability, unfavorable absorption properties, as well as poor receptor subtype 
selectivity. Nevertheless, they can be used as a template in order to synthesize modified 
peptides, called peptidomimetics, which are endowed with increased pharmacological 
activities.  
In a successfully designed peptidomimetic, two structural factors must have been taken 
into account: 1) a favorable docking in the binding site of the receptor target, if necessary 
the conformation can be stabilized by introduction of elements conferring rigidity such as 
bridges of various length between different parts of the molecule; 2) the spatial orientation 
of certain structural motifs (e.g. functional groups, polar and hydrophobic moieties) 
corresponds to the display in the bioactive conformation of the peptide, so that the 
required interactions (e.g. hydrogen bonds, electrostatic or hydrophobic interactions) can 
occur [156]. 
One possible strategy to favor the formation of bioactive conformations is modifying the 
side chain of amino acids [157]. In fact, the field of amino acids modifications has gained a 
big relevance in recent years, particularly with the emergence of new building blocks that 
allow introducing chemical and functional diversity into molecules with therapeutic 
potential. 
Since the pharmacophoric motif of the most active peptide sequence (C18) is 
characterized by aromatic rings and idrofobic residues, it is possible to project 
peptidomimetics in order to modulate the aromatic rings distance from the peptide 
backbone. In particular, Phe3 and Phe4 residues of C18 can be replaced by aminobenzilic 
derivatives, such as Nε-benzylated Lys and its shorter homologues, in order to evaluate 
the influence of  the more flexible pharmacoforic motif on the binding process.   
 With these ideas in our mind, we focused on the development of an efficient synthetic 
route to obtain modified on their side chain, via N-alkylation  reaction, Nα-Fmoc amino 
acids suitable to be introduced into a peptide sequence. The aim has been to set out a 
mild and general N-alkylation procedure which does not affect the stereochemistry of the 
amino acids chiral center, neither other sensitive functional/protective groups (i.e: the α-
COOH and Fmoc/Boc groups)  also present on the substrate. 
 
 
5.1  New N-alkylation procedure of Fmoc-amino acid derivatives 
 
Many different strategies [158-162] have been developed to obtain Nα-Alkyl amino acids, 
including reductive methods, Mitsunobu condition, direct alkylation by halides in presence 
of strong bases DBU [163, 164], NaOH [165], NaH [165, 166],  LiOH [167]  and usage of 
diazomethane in some case of methylation [168]. At the best of our knowledge, there are 
only few examples in literature that describe the side chain N-alkylation of amino acids 
[169, 170]. Yan-Mei Li method employs reductive conditions in order to obtain the Nε-
methyl lysine. The most cited Kessler protocol employs alkyl halides in presence of DBU 
or Mitzunobu condition in order to Nδ-alkylate the ornithine in solid phase. Both Kessler‘s 
procedures require the protection of the ornithine Nα-NH2 with an Alloc group and this is 
performed by an additional synthetic step. 
Most of the cited protocols protect the amino group as sulfonamide, by using the 
nitrobenzensulfonyl group (Ns) [171-173] in order to synthesis  mono-N-alkylated peptides 
[174]. In fact, the Nosyl group require mild conditions for its deprotection and is compatible 
with Fmoc solid phase synthesis [175], due to its stability under acidic (HCl) as well as 
basic (NaOH) conditions. 
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 We have previously described an efficient synthetic strategy to prepare o-Ns protected 
Fmoc-amino acids under mild conditions, in a rapid way and without resorting to any 
purification step. The products obtained (Fmoc-Lys(Ns)-OH, Fmoc-Orn(Ns)-OH, Fmoc-
Dab(Ns)-OH and Fmoc-Dap(Ns)-OH) were successfully employed as building blocks in 
solid phase synthesis [176]. Starting from these results, as next step we focused on the 
development of a synthetic procedure for  N-alkylation of the above mentioned Fmoc-
amino acids derivatives. In this contest, it is worth noting that the reaction conditions of the 
cited N-alkylation protocols are not compatible with Fmoc-group, since they employs quite  
strong basic conditions. So, we tried the traditional approach (K2CO3, halide, DMF) on the 
above mentioned amino acid derivatives previously synthesized [176].  This method hardly 
provided the mono-N-alkylated amino acids, moreover the separation of the product from 
salts was totally unsuccessful.  
Therefore, we developed an alternative and more practical synthetic route which employs 
only 4 Ǻ molecular sieves in order to promote the N-alkylation with halides in absence of 
any other base. 
Next, we performed the alkylation reaction on  several  Fmoc-amino acids previously  
protected on their side chain with Ns group (Fmoc-Lys(Ns)-OH, Fmoc-Orn(Ns)-OH, Fmoc-
Dab(Ns)-OH Fmoc-Dap(Ns)-OH) [176]. As shown in Scheme 3, each amino acid 
derivative was dissolved in DMF at room temperature and treated with the appropriate 
alkyl halide in presence of activated 4 Ǻ molecular sieves. 
The optimized N-alkylation procedure was explored toward a wide range of alkyl halides 
and, for each of them,  the reaction time and the relative yield are summarized in Table 2.  
 
 
Scheme 3 Synthetic strategy of mono-N-alkylated amino acids 
 
 
In particular, the N-alkylation reactions with benzyl and 3-phenylpropyl groups were 
performed by using the appropriate bromide and then repated by using the corresponding 
chloride. As expected, the employed halides did not react equally [177, 178].  After 24 h 
we could recover compound 1k and 4k with a yield around 50% (Table 2), while 1a and 4a 
were obtained in almost quantitative yield (>95%).  Concerning 1l and 4l,  the chlorides 
promoted a minimal conversion, which was characterized by  a reaction yield lower than 
5% (Table 2), while the bromides were successful in producing  1c and 4c ( yield of 90-
95%). 
It is known that while the side chain pKa of Lys, Orn and Dab is very similar, this value for 
Dap is lower by one unit [179].  Nevertheless, as suggested by the similar reaction yield 
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obtained for all amino acid derivatives (Lys, Orn, Dab and  Dap) alkylated by the same 
halides, the same nucleofilicity toward the same alkylating agent has been shown by Lys, 
Orn and Dab as well as Dap (in Table 2, compare yield of 1a, 2a, 3a, 4a; 1b and 4b; 1g 
and 4g; 1h and 4h; 1i and 4i). 
 
 
It is worth noting a decrease of reaction rate with the increase of the amino acid side 
chain length, for instance, the substitution reaction for compounds like 4c, 4d and 4f 
proceeds so slowly that by-products formation was also observed. Several effects are 
likely to contribute to a great decrease in reaction rate and yield (4c < 4d, 4f < 1f), like the 
presence of not particularly electron-rich (4d) or sterically hindered (4f) substituents on the 
alkyl bromide central carbon. As a consequence, the reaction yields observed for these 
compounds were lower than what expected.  
In general, the highest yield values were found for the most electron-rich alkyl bromides 
(see Table 2, yield of 1a, 1b, 1c, 1g, 2a, 3a, 4a, 4b, 4g).  In any case of yield around 90%,  
the compound obtained can be used as crude product for the subsequent peptide 
synthesis, after centrifugation that allows elimination of the molecular sieves, while for all 
compounds characterized  by a yield lower than 75%, it was necessary to purify the final 
product by RP-HPLC. In these cases, the purification also allows to recover any unreacted 
amino acid which can be employed again for alkylation reactions. 
 In order to further study the developed N-alkylation procedure promoted by molecular 
sieves, we performed the N-benzylation of the following Fmoc-diaminopropionic acid 
derivatives, Fmoc-Dap(Boc)-OH, Fmoc-Dap(Mtt)-OH and Fmoc-Dap(Dde)-OH (Figure 28), 
which are among the most used in peptide solid phase synthesis. As showed in Figure 28, 
the reaction was successful for each of these differently protected diaminopropionic acid 
derivative, even though it proceeded slower (24 h) than the same N-benzylation performed 
on Fmoc-Dap(Ns)-OH (15 h).  Moreover, the formation of 5a and 6a is also characterized 
by a slightly lower yield (75 %), compared with 1a (>95 %). In fact, the synthesis of 5a 
resulted incomplete, while the synthesis of 6a produced some by-products,  as a 
Table 2. Mono-N-Alkylation efficiency of each Fmoc-amino acids with respect to the employed halides. 
compound time (h) yield (%) R-X compound time (h) yield (%) R-X 
1a 15 >95 Br-Bn 3a 18 >95 Br-Bn 
1b 15 95 Br-(CH2)2-Ph 4a 22 >95 Br-Bn 
1c 15 95 Br-(CH2)3-Ph 4b 22 90 Br-(CH2)2-Ph 
1d 24 90 Br-(CH2)2-CH3 4c 24 <70 Br-(CH2)3-Ph 
1e 35 60 Br-(CH2)5-CH2=CH2 4d 28 75 Br-(CH2)2-CH3 
1f 38 70 Br-CH(Ph)2 4f 48 50 Br-CH(Ph)2 
1g 18 95 Br-CH2-Naph 4g 22 90 Br-CH2-Naph 
1h 15 >95  Br-CH2-CO2-C(CH3)3 4h 18 95 Br-CH2-CO2-C(CH3)3 
1i 15 >95              I-CH3 4i 18 95 I-CH3 
1j 15 95 I-CH2-CH3 4j 22 80 I-CH2-CH3 
1k 24 50 Cl-Bn 4k 24 50 Cl-Bn 
1l 24 <5 Cl-(CH2)3-Ph 4l 24 <5 Cl-(CH2)3-Ph 
2a 18 >95 Br-Bn     
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consequence for these building blocks a purification step is required before being 
employed in peptide synthesis. All in all, the proposed N-alkylation methodology resulted 
validated for different amino protecting groups. 
 
 
 
 
 
 
 
Figure 28 N-benzylation of differently 
protected Fmoc-diaminopropionic acid 
derivatives and relative reaction times 
and yields. 
 
 
 
 
 
 
 
 
 
 
5.2  Synthetic strategy to incorporate amino-alkylated building blocks into a peptide 
sequence 
 
In order to demonstrate the practical applicability of the functionalized amino acids as 
building blocks, we decided to introduce 1a, into a peptide sequence by using the standard 
Fmoc-based solid phase protocol (Scheme 4). 
 
 
 
 
 
 
Scheme 4  Introduction of  N-alkylated 
aminoacids into solid supported generic 
peptide (Fmoc-Gly Wang Resin, 0.8 mmol g
-
1
. TFA = trifluoroacetic acid; TIS = 
triisopropylsilane). 
 
 
 
 
 
 
 
 
As preliminarily shown by Kaiser test result and confirmed by LC-MS analysis on the crude 
products obtained upon cleavage from the resin, the desired alkylated peptide was found 
with a low yield ( data not shown). It is likely that the sterical hindrance of the introduced 
substituent and the nitrobenzensulfonyl (nosyl) groups on the side amino group makes the 
coupling of N-alkylated amino acid with the peptide sequence on the resin difficult. 
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Therefore, a solution phase coupling, in DMF with standard carboxyl activation 
PyBop/HOBt/DIPEA, of 1a with H-Ile-OtBu was performed (Scheme 4). The corresponding 
dipeptide 8a was recovered with quantitative yield and high purity, after treatment with 
trifluoroacetic acid in order to remove tBu group. As subsequent step, 5a was introduced 
into a peptide sequence in solid phase using standard Fmoc-chemistry (Scheme 4). After 
cleavage from resin, the alkylated peptide 9a, fully characterized by LC-MS analysis, was 
obtained with a yield of around 70% (Figure 29). This result confirmed the reliability of the 
alkylation method developed, since it was proven to fit well with Fmoc chemistry. 
 
 
Figure 29 HPLC profile of 9a crude product. 
 
 
 
 
In conclusion, by using only molecular sieves to promote the reaction, a mild, scaleable 
and efficient solution phase procedure for side chain N-alkylation of Fmoc-amino acids 
was developed. It results completely innovative, since in literature, at the best of our 
knowledge, it is not described any example of N-alkylation reaction performed with halides 
and molecular sieves as base. The proposed N-alkylation methodology was validated for 
different amino protecting groups, but the best results were obtained by using o-Ns 
protected Fmoc-amino acids, which represent readily available starting materials. In fact, 
the employed Fmoc-amino acids  are rapidly and efficiently protected with Ns group,  and 
affords the desired mono N-alkylated compound in high yield.  
For the majority of the employed halides, the procedure is a one-pot synthesis which 
avoids the purification after each reaction step. Moreover, it allowed the production of the 
desired compound in synthetically useful yield for the subsequent peptide chain assembly. 
Thus, the developed mothodology enables to introduce different substituents on the side 
chain of peptides C18 and to synthesize a great number of peptidomimetics, with the final 
goal of modulating the type and the distance of the aromatic pharmacophoric groups from 
the peptide backbone. 
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6. Conclusions and future perspectives 
 
On the basis of a three-dimensional structures of both SDF-1 protein and vMIP-II N-
terminal segment, a sequence-structure comparison between the N-terminal regions of 
this two proteins led to the design and synthesis of 18-membered peptide library. Each of 
this compound were evaluated for their ability to modulate CXCR4/SDF-1 axis function, in 
order to understand singular event concerning receptor activation. The pattern of biological 
responses elicited by these peptides was, however, very various, the behavior varying 
from agonism to antagonism, to inactivity for a same compound in different tests, and, 
more intriguingly, showing hints of non-additivity for their interaction with CXCR4 receptor 
in the presence of SDF-1. The lack of direct information about the true bioactive 
conformations of our templates prevents any simple evaluation of these effects, but further 
activity is planned to address this issue.  
In fact, the results obtained can not be explained by simple models for receptor 
activation/inhibition and suggest more complex interpretations, possibly involving direct 
SDF-1-peptide interactions and/or influence on symmetry, stoichiometry or structural 
variations of the homo- or hetero-oligomeric state of CXCR4 receptor. These features, 
while prompting for new studies, open new perspectives in obtaining more selective 
compounds toward different biological pathways involving CXCR4 receptor. In this regard, 
the forthcoming activity will be focused on the development of peptidomimetics that allow 
stabilizing the so-called 'bioactive' conformation, that is the peptide conformation required 
for receptor binding and activation. Moreover, dimers of the most active peptides will be 
also synthesized and tested for their biological activity, in order to evaluate any potential 
improvement of it compared with the activity exerted by the corresponding monomeric 
peptide sequence. 
Concerning the in vivo biological assay, it was found a dramatic decrease in mice 
metastases number induced by the treatment with three of the newly developed peptides. 
These results strongly suggested to continue the animal experimentation in order to select 
potential therapeutics among the already available molecules.         
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7. Material and methods  
 
7.1 Computational methods 
 
The designed peptides were energy minimized with NAMD [180] package using 
Charmm22 force field [181] and then subjected to Molecular dynamics (MD) simulations in 
solvent by confining each peptide in rectangular TIP3P water boxes, with a minimal 
distance from the solute atoms to the box walls of 12 Å. Counterions (Na+ or Cl-) were 
added to neutralize the system. Particle mesh Ewald method was applied to calculate 
long-range electrostatics interactions, setting to 14 Å the nonbonded cutoff. The solvated 
molecules were then energy minimized through 1000 steps with solute atoms restrained to 
their starting positions using a force constant of 1 kcal mol-1Å-1 prior to MD simulations. 
After this, the molecules were submitted to 125 ps of equilibration at constant pressure, to 
adjust water density, and gradually heated to 310 K, keeping the peptide fixed in the first 
50 ps and restrained, with stepwise (25 ps) decreasing force constant from 100 to 1 kcal 
mol-1Å-1 during the last 75 ps. Production runs were carried out for 5 ns using a timestep 
of 1 fs. Snapshots from production run were saved every 1000 steps and analyzed with 
NAMD program. Model figures were made with MOLMOL program [182]. 
 
 
7.2 Peptide synthesis  
 
Solid-phase peptide synthesis was performed on a fully automated Multisyntech Syro I 
synthesizer. Analytical RP-HPLC runs were carried out on a HP Agilent Series 1100 
apparatus using a Phenomenex (Torrance, CA) C18 column, 4.6 · 250 mm with a flow rate 
of 1.0 mL min-1. Preparative RP-HPLC was carried out on a Shimadzu 8A apparatus 
equipped with an UV Shimadzu detector using a Phenomenex (Torrance, CA) C18 
column, 22 · 250 mm with a flow rate of 20 mL min-1. For all the RP-HPLC procedures the 
system solvent used was H2O 0.1% TFA (A) and CH3CN 0.1% TFA (B), with a linear 
gradient from 5% to 70% B in 30 min. Mass spectral analyses were carried out on 
Finnigan Surveyor MSQ single quadrupole electrospray ionisation mass spectrometer 
coupled with a Finnigan Surveyor HPLC (Finnigan/Thermo Electron Corporation San Jose, 
CA, USA). 
The peptide synthesis was performed by solid phase method using the standard Fmoc 
procedures. PyBOP, HOBt, all Fmoc-amino acid derivatives were purchased from 
Calbiochem-Novabiochem (Laufelfingen, Switzerland). All other chemicals were obtained 
from Aldrich (St. Louis, MI), Fluka (Milwaukee, WI) or LabScan (Stillorgan, Dublin, Ireland) 
and were used without further purification, unless otherwise stated. 
The first amino acid was loaded on Wang resin according to literature protocol [183] and 
the loading was evaluated by Fmoc test. All couplings were performed twice for 30 min in 
DMF, by using an excess of 4 equiv for each amino acid coupling. 
The peptide cleavage from the solid support and the simultaneous removal of all protecting 
groups from the amino acid residues was carried out by suspending the fully protected 
compound-resins in TFA/H2O/EDT (94:4:2) for 3 h followed by filtration. The solution was 
then concentrated and the crude product isolated by precipitation into cold diethyl ether. 
The precipitate was collected by centrifugation and dried in vacuo (over KOH pellets). The 
cyclisation reaction, by disulphide bond formation between the two Cys residues, was 
performed by dissolving the crude peptide (final concentration 10-4M) in 0.1M solution of 
NH4HCO3 in water to promote the oxidation reaction. After 4 h the reaction mixture was 
concentrated and the desired compound isolated by chromatographic purification. 
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Compounds C1-C6 and C13-C18 
Fmoc-Arg(Pbf)-OH was the first amino acid derivative attached to the Wang resin (0.80 
mmol/g calcd substitution; 0.100 g resin; 0.080 mmol scale) for compounds C13, C14 and 
C15, while Fmoc-Cys(Trt)-OH was loaded on the same resin as first amino acid residue 
(0.80 mmol/g calcd substitution; 0.100 g resin; 0.080 mmol scale) for all other molecules. 
The peptide chains were then elongated by sequential coupling and Fmoc deprotection of 
appropriate amino acid derivatives (Fmoc-Ala-OH; Fmoc-Tyr(tBu)-OH; Fmoc-Phe-OH; 
Fmoc-His(Trt)-OH; Fmoc-Trp(Boc)-OH). The synthesis was ended with the acetylation 
(4.7% acetic anhydride  and 4% pyridine in DMF) of the N-terminal amino acid residue for 
compounds C4, C5, and C6. Following the protocol described in the general procedures 
paragraph, the peptides were cleaved from the solid support and freed from all the 
protecting groups at the same time.  The final oxidation reaction led to cyclised peptides by 
disulphide bond formation between the two cysteine residues. 
RP-HPLC purification and mass spectrometry analysis confirmed the presence of the 
desired compounds. C1: tR =13.83 min; [M+H]
+=702.30 (calcd=702.27); C2: tR=15.20 min; 
[M+H]+ =728.96 (calcd=728.27); C3: tR=17.12 min; [M+H]
+ =672.95 (calcd=673.27); C4: 
tR=16.23 min; [M+H]
+ =744.50 (calcd= 744.83); C5: tR=17.12 min; [M+H]
+ =770.50 
(calcd=770.27); C6: tR=19.22 min; [M+H]
+ =715.36 (calcd=715.27); C13: tR =12.30 min; 
[M+H]+=929.58 (calcd=929.41); C14: tR =13.60 min; [M+H]
+=955.58 (calcd=955.41); C15: 
tR =15.30 min; [M+H]
+=900.58 (calcd=900.41); C16: tR =13.70 min; [M+H]
+=929.35 
(calcd=929.41); C17: tR =14.30 min; [M+H]
+=955.68 (calcd=955.41); C18: tR =15.70 min; 
[M+H]+=900.09 (calcd=900.41). 
 
Compounds C7-C12 
For each compound 0.200 g of Rink Amide MBHA resin (0.28 mmolg-1 substitution; 0.056 
mmol scale) were used. The synthesis of the peptide chains was performed by sequential 
coupling and Fmoc deprotection of the appropriate amino acid derivatives. The acetylation 
procedure, the same described for the other molecules, was performed at the N-terminal 
amino acid residue of compounds C10, C11 and C12. After completion of the synthesis, 
the peptide cleavage from the solid support and the deprotection of all amino acid residues 
were carried out as described in the previous paragraph. 
The crude products obtained were then cyclised by disulphide bond formation, fully 
purified by RP-HPLC and characterized by mass spectrometry. C7: tR=14.22 min; [M+H]
+ 
=701.37 (calcd=701.27); C8: tR=16.90 min; [M+H]
+ = 727.09 (calcd=727.27); C9: tR=18.21 
min; [M+H]+ =672.42 (calcd=672.27); C10: tR=17.84 min; [M+H]
+ =743.40 (calcd=743.83); 
C11: tR=19.22 min; [M+H]
+ =769.70 (calcd=769.27); C12: tR=19.22 min; [M+H]
+ =769.70 
(calcd=769.27); 
 
 
7.3 Biological test 
 
Cell Culture 
PES43, human melanoma cell line were grown at 37 °C in 5% CO2 in IMDM with 10% fetal 
calf serum (FCS), 2 mM glutamine, 1 mM sodium pyruvate, 50 µg/ml penicillin, 50 µg/ml 
streptomycin. CCRF-CEM, human T-Leukemia cell line were grown in RPMI-1640 with 
10% fetal calf serum (FCS) and 2 mM glutamine. B16-CXCR4 murine melanoma cell line, 
previously transfected with CXCR4 plasmid, were grown at 37 °C in 5% CO2 in IMDM with 
10% fetal calf serum (FCS) and 2 mM glutamine 50 µg/ml penicillin, 50 µg/ml streptomycin 
and 100 ug/ml G418. 
B16 cells  were transfected with CXCR4 according to FuGENE 6 protocol (Roche Applied 
Science, Indianapolis, IN). Briefly, 20 μg/well of CXCR4 plasmid and 30 μl/well of FuGENE 
6 were mixed in 500 μl serum free IMDM (B16) medium and incubated at room 
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temperature for 15 minutes. Following incubation, the plasmid/FuGENE 6 mixture was 
added to the cells in 6-well plates. 48 hours later and geneticin selection started (500 
μg/mL of G418) (Invitrogen, Carlsbad, CA). 
 
Migration assay and wound closure 
Migration was assayed in 24-well Transwell chambers (Corning Inc., Corning, NY) using 
inserts with 8-µm pore membrane. Membranes were precoated with collagen (human 
collagen type I/III) and fibronectin (20 µg/ml each). PES43 cells were placed in the upper 
chamber (2.5x105 cells/well) in IMDM containing 1% BSA (migration media), and 20 ng/ml 
CXCL12 was added to the lower chamber in triplicate. After 16 hours incubation, cells on 
the upper surface of the filter were removed using a cotton wool swab; migration of cells in 
migration media alone was compared with migration in media containing 20 ng/ml 
CXCL12. The cells were counted in ten differents fields (original magnification x40). The 
migration index was defined as the ratio between migrating cells in the experimental group 
and migrated cells in the control group. For the wound closure assay, tested cells were 
allowed to reach confluence  in six-well plates containing serum depleted growth medium 
and scratched with pipette tips to make wounds. The wound closure was observed 
microscopically 6 hours post-wounding (OKO Time Lapse). 
 
Flow Cytometry and peptide binding evaluation 
CCRF-CEM cells were washed in PBS and incubated for 30 min at 4°C with anti-CXCR4 
antibody PE conjugated (FAB 170P, clone 12G5, R&D Systems, Minneapolis, MN, USA) 
or mouse IgG2a PE conjugated as negative control. After three washes in PBS, the cells 
were analysed by FACScan cytofluorometer (Becton Dickinson Immunocytometry 
Systems, Mountain View, CA, USA). CCRF–CEM cells were incubated with 10 µM 
peptides or AMD3100 in RMPI-1640 with 2mM glutamine for 30min at 37 °C, 5% CO2 and 
labelled with an anti-CXCR4 PE-antibody. The number of antibody-molecules bound was 
calculated comparing GeoMean value with standard beads (PE Fluorescence 
quantification Kit, BD Inc.). 
 
Calcium mobilization assay.  
For the calcium flux studies a 2 mg/mL stock solution of Fluo-3 acetoxymethylester 
(Molecular Probes, Leiden, the Netherlands) in anhydrous DMSO was used. A 20% w/v 
stock solution of the detergent pluronic acid F-127 (Molecular Probes) was also prepared 
in DMSO. CCRF–CEM cells were resuspended in cell loading buffer (PBS, 1% FCS, 1 
mmol/L MgCl2, and 1 mmol/L CaCl2) at a concentration of 0.5 x106/mL. Four microliters of 
Fluo-3AM and four microlitres of Pluronic acid were added to each sample to increase 
Fluo-3 acetoxymethylester solubility and improve dye loading into the cells. Followed one 
hour in agitation at room temperature. Thereafter, cells were washed twice with cell 
loading buffer and incubated at 37°C for 15 minutes. First, untreated cells were examined 
by flow cytometric analysis for 10 seconds in fluorescence versus time to establish a 
baseline. Then, chemokines were added as indicated and chemokine induced 
fluorescence was measured.  
 
Immunoblotting 
Cells were homogenized in lysis buffer (40 mM Hepes pH 7,5, 120 mM NaCl, 5 mM MgCl2, 
1 mM EGTA, 0,5 mM EDTA, 1% Triton X-100) containing protease (Complete Tablets- 
EDTA-free, Roche) and phosphatase inhibitors (20 mM a-glycerol-phosphate, 2,5 mM Na-
pyrophosphate). Total lysate was cleared by centrifugation at 15,000g for 20 min. Protein 
concentration of supernatant was measured using Bio-Rad protein assay. 30µg of extracts 
were denatured and resolved by SDS-PAGE (12%) gel electrophoresis, transferred to a 
Hybond ECL nitrocellulose membrane (Amersham Biosciences, Freiburg, Germany) by 
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electroblotting at 250 mA for 2 hours. The following primary antibodies were used: anti-P-
ERK(sc 7383, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and anti-ERK2 (sc 
154G, Santa Cruz Biotechnology). Anti-mouse and anti-goat IgG coupled to peroxidase 
were used as secondary antibodies (Sigma-Aldrich Corp., St. Louis, Missouri, USA) and 
the signal was revealed through Chemoluminescent detection kit (ECL detection kit, 
Amersham Biosciences, Freiburg, Germany). 
 
In Vivo Assays 
Twenty-five 7 to 8 week-old female C57BL/6 mice weighing approximately 20 g were 
inoculated into the tail vein with 5 x 105 B-16 –CXCR4 cells preincubated for 30 minutes 
with: 1) PBS, 2) AMD3100 (10μM), 3) C16 (10μM), 4) C18 (10μM), 5) C1 (10μM). Six 
hours later the intraperitoneal treatment started with  AMD3100 (1.25mg/kg) and peptides 
(2mg/kg) in sterile PBS were administered i.p. once daily, 5 days on and two days off, for a 
period of 2 weeks. Mice were euthanized after 28 days by cervical dislocation for gross 
inspection of lungs. 
 
 
7.4 N-alkylation reaction 
 
Chemicals and Equipment 
All purchased chemicals and solvents were used without further purification, unless 
otherwise stated. Solid-phase peptide synthesis was performed on a fully automated 
Multisyntech Syro I synthesizer. Molecular sieves type 4 Å (beads, diameter 1.6 mm) were 
activated by heating at 280 °C for 4h under vacuum and atmosphere of Ar. 
 
LC/MS analysis 
 Analytical RP-HPLC runs were carried out using a C18 column, 4.6 × 250 mm with a flow 
rate of 1.0 mL min-1. Preparative RP-HPLC was carried out  using a C18 column, 22 × 250 
mm with a flow rate of 20 mL min-1. For all the RP-HPLC procedures the system solvent 
used was: H2O 0.1% TFA (A) and CH3CN 0.1% TFA (B), with a linear gradient from 5% to 
70% B in 30 min (gradient 1) or from 40% to 95% B in 30 min (gradient 2) and detection at 
210 nm and 280 nm. LC-ES-MS data were obtained using a single quadrupole 
electrospray ionisation mass spectrometer coupled with an HPLC apparatus. HRMS were 
run on a Micromass QTOF mass spectrometer.  
 
NMR analysis 
1H and 13C NMR spectra were recorded at 400 and 100 MHz respectively on spectrometer 
equipped with a z-gradient 5 mm triple-resonance probe head. Samples were prepared in 
tubes with a diameter of 5 mm using 0.5 ml of deuterated solvent. The chemical shifts are 
reported in units of  ppm on the δ scale relative to solvent signal used (CDCl3 7.26 ppm for 
1H NMR and 77.00 ppm for 13C NMR).
 
1H NMR assignments were based on homo-
decoupling experiments.  
Optical rotations were measured using a 1 mL cell with a 10 mm path length. 
 
General procedure for N-Alkylation promoted by molecular sieves. 
A solution of  Fmoc-Xaa(Ns)-OH in DMF (50 mg/ml), previously synthesized by using the 
already published protocol (De Luca et al. 2005), was added under Ar atmosphere in a 
round-bottom flask containing 4 Å molecular sieves previously activated at 280°C for 4 h 
under vacuum. After few minutes the alkylating reagent was added (1.5 eq). The reaction 
was stirred at room temperature and followed by analytical RP-HPLC until disappearance 
of the starting compound. The mixture was centrifugated and the precipitate was washed 
with DMF. Then, the surnatant was concentrated under vacuum and the crude product 
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was purified by HPLC to be fully characterized by mass spettrometry and NMR 
spectroscopy. 
 
 
Nα-(9-Fluorenylmethoxycarbonyl)-Nβ-benzyl–N
‘
β-2-Nitrobenzensulfonyl-L-2,3-
Diaminopropionic acid 1a, 1k HPLC: tR = 23.581 min (gradient 2); 
1
H NMR (400 MHz, CDCl3): 
 8.07 & 7.81 (2d, J = 7.1 Hz, 2H, Ns-H3,6), 7.77 & 7.58 (2d, J = 7.6 Hz, 4H, Fmoc-H1,4,5,8), 7.68 
(m,  2H, Ns-H4,5), 7.41 & 7.32 (2t, J = 7.2 Hz, 4H, Fmoc-H2,3,6,7), 7.37 (m, 5H, Ph-H2,3,4,5,6), 5.23 
(m, 2 H, CH2-Ph), 4.48 (br, 1 H, Dap-CH
4.36 (d, J = 6.8 Hz, 2 H, Fmoc-CH2), 4.20 (t, J = 6.8 
Hz, 1 H, Fmoc-CH), 3.58 (br, 2 H, Dap-CH2
 13C NMR (100 MHz, CDCl3): 
 126.01; 127.64; 128.28; 129.06;129.25; 
131.50; 133.39; 134.27; 141.77; 144.10; 156.59; 169.87. ES-MS: calcd (M + H
+
), 601.15; found, 
m/z 601,35; calcd (M + Na
+
), 623.15; found, m/z 623,89; HRMS (ESI)  Calcd for C31H27N3O8S, 
601.1557; Found, 601.1561; [α] D
 25
  = -15.7 (c = 0.3, CHCl3). 
 
Nα-(9-Fluorenylmethoxycarbonyl)-Nβ-2-phenylethyl–N
‘
β-2Nitrobenzensulfonyl-L-2,3-
Diaminopropionic acid 1b HPLC: tR = 23.97 min (gradient 2); 
1
H NMR (400 MHz, CDCl3):  
8.07 & 7.83 (2d, J = 6.8 Hz, 2H, Ns-H3,6), 7.78 & 7.60 (2d, J = 7.6 Hz, 4H, Fmoc-H1,4,5,8), 7.70 (m,  
2H, Ns-H4,5), 7.42 & 7.23 (2t, J = 7.2 Hz, 4H, Fmoc-H2,3,6,7), 7.32 (m, 5H, Ph-H2,3,4,5,6), 4.42 (m, 
3H, Dap-CH
CH2-CH2-Ph4.37 (d, J = 6.8 Hz, 2 H, Fmoc-CH2), 4.21 (t, J = 6.8 Hz, 1 H, 
Fmoc-CH), 3.51 (br, 2H, Dap-CH2
, 3.00 (t, J = 6.8 Hz, 2H, CH2-CH2-Ph)
13
C NMR (100 MHz, 
CDCl3): 
67.53;
ES-MS: calcd (M 
+ H
+
), 615.17; found, m/z 615,52, calcd (M + Na
+
), 627.17; found, m/z 627,67; HRMS (ESI) Calcd 
for C32H29N3O8S, 615.1749; Found, 615.1754. [α] D
 25
  = -6.2 (c = 0.4, CHCl3). 
 
Nα-(9-Fluorenylmethoxycarbonyl)-Nβ-3-phenylpropyl–N
‘
β-2-Nitrobenzensulfonyl-L-2,3- 
Diaminopropionic acid 1c, 1l HPLC: tR = 25.48 min (gradient 2); 
1
H NMR (400 MHz, CDCl3):  
8.08 & 7.82 (2br, 2H, Ns-H3,6), 7.77 & 7.59 (2d, J = 7.6 Hz, 4H, Fmoc-H1,4,5,8), 7.70 (m,  2H, Ns-
H4,5), 7.41 & 7.19 (2t, J = 7.2 Hz, 4H, Fmoc-H2,3,6,7), 7.31 (m, 5H, Ph-H2,3,4,5,6), 4.39 (m, 3H, Dap-
CH
Fmoc-CH24.21 (m, 3H, Fmoc-CH  and CH2- CH2- CH2-Ph3.54 (br,  2H, Dap-CH2
), 
2.70 (t, J = 6.8 Hz, 2H, -CH2-CH2-CH2-Ph), 2.01 (m, 2H, -CH2-CH2-CH2-Ph) 
13
C NMR (100 MHz, 
CDCl3):
 ES-MS: calcd (M 
+ H
+
), 629.18; found, m/z 629.41, calcd (M + Na
+
), 651.18; found, m/z 651.80; HRMS (ESI) Calcd 
for C33H31N3O8S, 629.1867; Found, 629.1895. [α] D
 25
  = -5.8 (c = 0.3, CHCl3). 
 
Nα-(9-Fluorenylmethoxycarbonyl)-Nβ-propyl–N
‘
β-2-Nitrobenzensulfonyl-L-2,3-
Diaminopropionic acid 1d HPLC: tR = 22.14 min (gradient 2); 
1
H NMR (400 MHz, CDCl3):  
8.11 & 7.83 (2br, 2H, Ns-H3,6), 7.78 & 7.60 (2d, J = 7.6 Hz, 4H, Fmoc-H1,4,5,8), 7.71 (m,  2H, Ns-
H4,5), 7.41 & 7.33 (2t, J = 7.2 Hz, 4H, Fmoc-H2,3,6,7), 4.45 (br, 1H, Dap-CH
4.37 (d, J = 7.2 Hz, 2 
H, Fmoc-CH2), 4.22 (t, J = 6.8 Hz, 1H, Fmoc-CH), 4.18 (t, J = 6.8 Hz, 2H, -CH2-CH2-CH3), 3.58 
(br, 2H, Dpr-CH2

), 1.71 (m, 2H, -CH2-CH2-CH3), 0.96 (t, J = 7.6, 3H, -CH2-CH2-CH3  
13
C NMR 
(100MHz,CDCl3):
 ES-MS: calcd (M + H+), 553.15; 
found, m/z 553.21, calcd (M + Na
+
), 575,15 found, m/z 575,75; HRMS (ESI) Calcd for 
C27H27N3O8S, 553.1498; Found, 553.1503. [α] D 
25
  = -8.3 (c = 0.1, CHCl3). 
 
Nα-(9-Fluorenylmethoxycarbonyl)-Nβ-1-heptenyl–N
‘
β-2-Nitrobenzensulfonyl-L-2,3- 
Diaminopropionic acid 1e HPLC: tR = 26.20 min (gradient 2); 
1
H NMR (400 MHz, CDCl3):  
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8.10 & 7.83 (2br, 2H, Ns-H3,6), 7.77 & 7.59 (2d, J = 7.6 Hz, 4H, Fmoc-H1,4,5,8), 7.71 (m,  2H, Ns-
H4,5), 7.41 & 7.33 (2t, J = 7.2 Hz, 4H, Fmoc-H2,3,6,7), 5.77 (m, 1H, -CH2-CH=CH2), 5.00 & 4.95 
(2m, 2H, -CH2-CH=CHa,b), 4.44 (m, 1 H, Dap-+-CH
4.36 (d, J = 7.2 Hz, 2 H, Fmoc-CH2), 4.21 
(m, 3 H, Fmoc-CH and -CH2-(CH2)4-CH=CH2 ), 3.57 (br, 2 H, Dpr-CH2

), 2.06 (m, 2H, -(CH2)4- 
CH2-CH=CH2),1.69 & 1.40 (2m, 8H, -(CH2)4- CH2-CH=CH2 )
  13
C NMR (100 MHz, CDCl3):  
25.67; 28.72; 28.83; 33.96; 45.45; 47.46; 54.38; 67.032; 67.93; 115.09; 120.49; 125.58; 125.97; 
127.61; 128.27; 128.84; 128.98; 131.48; 133.38; 134.24; 139.04; 141.76; 144.11; 156.33; 170.04. 
ES-MS: calcd (M + H
+
), 607.20; found, m/z 607.64, calcd (M + Na
+
), 629.20; found, m/z 630.00; 
HRMS (ESI) Calcd for C31H33N3O8S, 607.1988; Found, 607.1996. [α] D
 25
  = -6.9 (c = 0.9, CHCl3). 
 
Nα-(9-Fluorenylmethoxycarbonyl)-Nβ-diphenylmethyl–N
‘
β-2-Nitrobenzensulfonyl-L-2,3- 
Diaminopropionic acid 1f HPLC: tR = 26.09 min (gradient 2); 
1
H NMR (400 MHz, CDCl3):  
8.00 & 7.79 (2d, J = 7.1 Hz, 2H, Ns-H3,6), 7.76 & 7.57 (2d, J = 7.6 Hz, 4H, Fmoc-H1,4,5,8), 7.66 (m,  
2H, Ns-H4,5), 7.42-7.31 (m, 14H, Fmoc-H2,3,6,7 and CH-(Ph)2-H), 6.90 (br, 1H, CH-(Ph)2), 4.55 (br, 
1H, Dap-CH
4.35 (d, J = 6.8 Hz, 2H, Fmoc-CH2), 4.19 (t, J = 6.8 Hz, 1H, Fmoc-CH), 3.59 (br, 
2H, Dap-CH2
13C NMR (100 MHz, CDCl3):  45.37; 47.48; 54.54; 68.07; 79.76; 120.51; 125.64; 
126.03; 127.53; 127.65; 128.31; 128.85; 128.92; 129.19; 129.28; 131.57; 133.38; 134.27; 139.52; 
141.78; 144.12; 156.42; 169.29. ES-MS: calcd (M + H
+
), 677.18; found, m/z 677,54; calcd (M + 
Na
+
), 699.18; found, m/z 700,02; HRMS (ESI) Calcd for C37H31N3O8S, 677.1831; Found, 
677.1847. [α] D
 25
  = -6.4 (c = 0.5, CHCl3). 
 
Nα-(9-Fluorenylmethoxycarbonyl)-Nβ-naphtylmethyl–N
‘
β-2-Nitrobenzensulfonyl-L-2,3- 
Diaminopropionic acid 1g HPLC: tR = 25.87 min (gradient 2); 
1
H NMR (400 MHz, CDCl3):  
8.02 & 7.84 & 7.76 & 7.64 & 7.56 & 7.50 & 7.45 & 7.39 & 7.30 (9m, 19H, Ns-H3,4,5,6 , Fmoc-
H1,2,3,4,5,6,7,8 , Naph-H2,3,4,5,6,7,8 ), 5.38 (m, 2H, CH2-Naph), 4.50 (br, 1H, Dap-CH
4.36 (d, J = 6.8 
Hz, 2H, Fmoc-CH2), 4.19 (t, J = 6.8 Hz, 1 H, Fmoc-CH), 3.58 (br, 2H, Dap-CH2

13
CNMR(100MHz,CDCl3):
 
ES-MS: calcd (M + H
+
), 651.17; found, m/z 651,32; calcd (M + Na
+
), 673.17; found, m/z 673,89; 
HRMS (ESI) Calcd for C35H29N3O8S, 651.1764; Found, 651.1783. [α] D 
25
  = -2.4 (c = 0.3, CHCl3). 
 
Nα-(9-Fluorenylmethoxycarbonyl)-Nβ-t-ButylAcetyl–N
‘
β-2-Nitrobenzensulfonyl-L-2,3-
Diaminopropionic acid 1h HPLC: tR = 22.998 min (gradient 2); 
1
H NMR (400 MHz, CDCl3):  
8.12 & 7.83 (2br, 2H, Ns-H3,6), 7.77 & 7.63 (1d & 1m, J = 7.6 Hz, 4H, Fmoc-H1,4,5,8), 7.68 (m,  2H, 
Ns-H4,5), 7.41 & 7.33 (2t, J = 7.2 Hz, 4H, Fmoc-H2,3,6,7), 4.87 & 4.40 (2d, J = 14 Hz, 2H, 
CH2CO2C(CH3)3), 4.58 (d, J = 6.4 Hz, 2 H, Fmoc-CH2), 4.38 (m, 1H, Dap-CH
 4.25 (t, J = 6.8 Hz, 
1 H, Fmoc-CH), 3.69 (br, 2 H, Dap-CH2
s, 9H, CH2CO2C(CH3)3).
 
13
C NMR (100 MHz, CDCl3): ; 
127.59; 128.19; 131.28; 133.14; 133.97; 141.69; 144.11;148.12; 156.29; 167.81; 169.76. ES-MS: 
calcd (M + H
+
), 625.17; found, m/z 625,70; calcd (M + Na
+
), 647.17; found, m/z 647,68; HRMS 
(ESI)  Calcd for C30H31N3O10S, 625.1730; Found, 625.1761; [α] D
 25
  = -6.5 (c = 0.4, CHCl3) 
 
Nα-(9-Fluorenylmethoxycarbonyl)-Nβ-methyl–N
‘
β-2-Nitrobenzensulfonyl-L-2,3-
Diaminopropionic acid 1i HPLC: tR = 18.088 min (gradient 2); 
1
H NMR (400 MHz, CDCl3):  
8.10 & 7.84 (2br, 2H, Ns-H3,6), 7.77 & 7.59 (2d, J = 7.2 Hz, 4H, Fmoc-H1,4,5,8), 7.71 (m,  2H, Ns-
H4,5), 7.41 & 7.33 (2t, J = 7.2 Hz, 4H, Fmoc-H2,3,6,7), 4.44 (m, 1H, Dap-CH
  4.35 (d, J = 6.4 Hz, 2 
H, Fmoc-CH2), 4.21 (t, J = 6.8 Hz, 1 H, Fmoc-CH), 3.81 (s, 3H, Nβ-CH3), 3.56 (br, 2 H, Dap-CH2
 
13
C NMR (100 MHz, CDCl3):  125.97; 127.59; 
128.24; 131.45; 133.37; 134.25; 141.73; 144.02; 157.29; 169.75. ES-MS: calcd (M + H
+
), 525.12; 
found, m/z 525,52; calcd (M + Na
+
), 547.12; found, m/z 547,88; HRMS (ESI)  Calcd for 
C25H23N3O8S, 525.1206; Found, 525.1210; [α] D
 25
  = -5.9 (c = 0.3, CHCl3). 
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Nα-(9-Fluorenylmethoxycarbonyl)-Nβ-ethyl–N
‘
β-2-Nitrobenzensulfonyl-L-2,3-
Diaminopropionic acid 1j HPLC: tR = 19.518 min (gradient 2); 
1
H NMR (400 MHz, CDCl3):  
8.10 & 7.83 (2br, 2H, Ns-H3,6), 7.77 & 7.59 (2d, J = 7.2 Hz, 4H, Fmoc-H1,4,5,8), 7.70 (m,  2H, Ns-
H4,5), 7.40 & 7.32 (2t, J = 7.2 Hz, 4H, Fmoc-H2,3,6,7), 4.43 (m, 1H, Dap-CH
, 4.36 (d, J = 6.8 Hz,  
2H, Fmoc-CH2,  4.25 (m, 3 H, Fmoc-CH, Nβ-CH2CH3), 3.57 (br, 2 H, Dap-CH2
t, J = 6.4 
Hz, Nβ-CH2CH3)
 
13
C NMR (100 MHz, CDCl3):  
126.00; 127.64; 128.29; 131.50; 133.41; 133.94; 134.27; 141.78; 144.11; 148.49; 156.33; 169.96. 
ES-MS: calcd (M + H
+
), 539.14; found, m/z 539,44; calcd (M + Na
+
), 561.14; found, m/z 561,38; 
HRMS (ESI)  Calcd for C26H25N3O8S, 539.1362; Found, 639.1398; [α] D
 25
  = -6.3 (c = 0.5, CHCl3) 
 
Nα-(9-Fluorenylmethoxycarbonyl)-Nγ-benzyl–N
‘
γ-2-Nitrobenzensulfonyl-L-2,4-
Diaminobutirric acid 2a HPLC: tR = 23.41 min (gradient 2); 
1
H NMR (400 MHz, CDCl3):  8.07 
& 7.78 (2br, 2H, Ns-H3,6), 7.67 & 7.58 (2md, 6H, Fmoc-H1,4,5,8 , Ns-H4,5),  7.41-7.32 (m, 9H, Fmoc-
H2,3,6,7  Ph-H2,3,4,5,6), 5.15 (m, 2 H, CH2-Ph), 4.47 (d, J = 6.8 Hz, 2 H, Fmoc-CH2)4.41 (m, 1 H, 
Dab-CH
, 4.18 (t, J = 6.8 Hz, 1 H, Fmoc-CH), 3.32 & 3.02 (2m, 2H, Dab-CH2
γ 2.12 & 1.75 (2m, 
2H, Dab-CH2
   
13
CNMR(100MHz,CDCl3):

ES-MS: calcd (M + H+), 615.65; found, m/z 616.16, calcd (M + Na+), 637.65; found, m/z 
637.85; HRMS (ESI) Calcd for C32H29N3O8S, 615.6523; Found, 616.6542. [α] D
 25
  = -17.7 (c = 0.3, 
CHCl3). 
 
Nα-(9-Fluorenylmethoxycarbonyl)-Nδ-benzyl–N
‘
δ-2-Nitrobenzensulfonyl-L-Ornithine 3a 
HPLC: tR = 23.77 min (gradient 2); 
1
H NMR (400 MHz, CDCl3):   8.11 & 7.80 (2br, 2H, Ns-H3,6), 
7.78 & 7.59 (2d, J = 7.6 Hz, 4H, Fmoc-H1,4,5,8), 7.69 (m,  2H, Ns-H4,5), 7.41 & 7.32 (2t, J = 7.2 Hz, 
4H, Fmoc-H2,3,6,7), 7.37 (m, 5H, Ph-H2,3,4,5,6), 5.18 (m, 2H, CH2-Ph), 4.41 (d, J = 6.8 Hz, 2 H, Fmoc-
CH2)4.37 (m, 1 H, Orn-CH
, 4.20 (t, J = 6.8 Hz, 1H, Fmoc-CH), 3.08 (m, 2H, Orn-CH2
δ 1.70 
(m, 2H, Orn-CH2
β
), 1.55 (m, 2H, Orn-CH2
γ  13C NMR (100 MHz, CDCl3): 

 ES-MS: 
calcd (M + H
+
), 629.18; found, m/z 629.52, calcd (M + Na
+
), 651.18; found, m/z 651.84; HRMS 
(ESI) Calcd for C33H31N3O8S, 629.1812; Found, 629.1822. [α] D
 25
  = -1.3 (c = 0.8, CHCl3). 
 
Nα-(9-Fluorenylmethoxycarbonyl)-Nε-benzyl–N
‘
ε -2-Nitrobenzensulfonyl-L-Lysine 4a, 4k 
HPLC: tR = 24.20 min (gradient 2); 
1
H NMR (400 MHz, CDCl3):  8.11 & 7.82 (2br, 2H, Ns-H3,6), 
7.77 & 7.60 (2d, J = 7.6 Hz, 4H, Fmoc-H1,4,5,8), 7.70 (m,  2H, Ns-H4,5), 7.40 & 7.31 (2t, J = 7.2 Hz, 
4H, Fmoc-H2,3,6,7), 7.35 (m, 5H, Ph-H2,3,4,5,6), 5.18  (m, 2H, CH2-Ph), 4.41 (d, J = 6.8 Hz, 2 H, 
Fmoc-CH2)4.38 (br, 1H, Lys-CH
, 4.22 (t, J = 6.8 Hz, 1 H, Fmoc-CH), 3.04 (m, 2 H, Lys-CH2
 ε 
1.82 & 1.65 (2m, Lys-CHa,b
 β
), 1.52 (m, 2H, Lys-CHa,b
 γ
) 1.32 (m, 2H, Lys-CHa,b
 δ13C NMR (100 
MHz, CDCl3):  22.40; 29.40; 32.60; 43.87; 47.64; 53.97; 67.59; 67.84; 120.49; 125.59; 125.90; 
127.59; 128.23; 128.93; 129.19; 131.56; 133.22; 134.02; 141.82; 144.24; 156.46;172.56. ES-MS: 
calcd (M + H
+
), 643.20; found, m/z 643.11, calcd (M + Na
+
), 665.20; found, m/z 665.81; HRMS 
(ESI) Calcd for C34H33N3O8S, 643.2031; Found, 643.2048. [α] D
 25
  = -6.1 (c = 0.4, CHCl3). 
 
Nα-(9-Fluorenylmethoxycarbonyl)-Nε-2-phenylethyl–N
‘
ε-2-Nitrobenzensulfonyl-L-Lysine 
4b HPLC: tR = 24.73 min (gradient 2); 
1
H NMR (400 MHz, CDCl3):  8.11 & 7.83 (2br, 2H, Ns- 
H3,6), 7.77 & 7.60 (2d, J = 7.6 Hz, 4H, Fmoc-H1,4,5,8), 7.70 (m,  2H, Ns-H4,5), 7.40 & 7.21 (2t, J = 
7.2 Hz, 4H, Fmoc-H2,3,6,7), 7.30 (m, 5H, Ph-H2,3,4,5,6), 4.48-4.28 (m, 5H, Lys-CH
Fmoc-CH2 , 
58 
 
CH2-CH2-Ph), 4.21 (t, 1H, J = 6.8 Hz, 1 H, Fmoc-CH), 3.03 (m, 2 H, Lys-CH2
ε 2.96 (t, 2H, J = 6.8 
CH2-CH2-Ph), 1.72 (m, 1H,  Lys-CH2
β
), 1.55-1.44 (m, 3H,  Lys-CH2
β
 and Lys-CH2
γ
), 1.24 (m, 2H, 
Lys-CH2
δ
). 
13
C NMR (100 MHz, CDCl3):   
67.52; 120.50; 125.60; 125.93; 127.24; 127.59; 128.25; 129.07; 129.39; 131.57; 133.25; 134.05; 
137.83; 141.82; 144.26; 148.60; 156.41; 172.61. ES-MS: calcd (M + H
+
), 657.21; found, m/z 
657.61, calcd (M + Na
+
), 679.21; found, m/z 679.81; HRMS (ESI) Calcd for C35H35N3O8S, 
657.2162; Found, 657.2182. [α] D
 25
  = -6.8 (c = 0.3, CHCl3). 
 
Nα-(9-Fluorenylmethoxycarbonyl)-Nε-3-phenylpropyl–N
‘
ε-2 Nitrobenzensulfonyl-L-Lysine 
4c, 4l HPLC: tR = 26.22 min (gradient 2); 
1
H NMR (400 MHz, CDCl3):  8.11 & 7.82 (2br, 2H, 
Ns-H3,6), 7.77 & 7.60 (2d, J = 7.6 Hz, 4H, Fmoc-H1,4,5,8), 7.70 (m,  2H, Ns-H4,5), 7.40 & 7.20  (2t, J 
= 7.2 Hz, 4H, Fmoc-H2,3,6,7), 7.29 (m, 5H, Ph-H2,3,4,5,6), 4.41 (d, 2H, J = 6.8 Hz, 2 H, Fmoc-
CH2)4.32 (m, 1H, Lys-CH
, 4.21 (t, 1H, J = 6.8 Hz, 1 H, Fmoc-CH), 4.16 (m, 2H, CH2-CH2-CH2-
Ph) 3.09 (m, 2 H, Lys-CH2
ε 2.68 (t, 2H, J = 7.6 CH2-CH2-CH2-Ph), 1.98 (m, 2H CH2-CH2-CH2-
Ph), 1.79 (m, 1H,  Lys-CH2
β
), 1.68-1.54 (m, 3H,  Lys-CH2
β
 and Lys-CH2
γ
), 1.38 (m, 2H, Lys-
CH2
δ
);    
13
C NMR (100 MHz, CDCl3):   65.51; 
67.56; 120.50; 125.61; 125.91; 126.65; 127.61; 128.25; 128.89; 129.03; 131.56; 133.24; 134.05; 
141.36; 141.84; 144.28; 148.60; 156.53; 172.76. ES-MS: calcd (M + H
+
), 671.23; found, m/z 
671.11, calcd (M + Na
+
), 693.23; found, m/z 693.81; HRMS (ESI) Calcd for C36H37N3O8S, 
671.2319; Found, 671.2340. [α] D
 25
  = -5.7 (c = 1.1, CHCl3). 
 
Nα-(9-Fluorenylmethoxycarbonyl)-Nε-propyl–N
‘
ε-2-Nitrobenzensulfonyl-L-Lysine 4d 
HPLC: tR = 22.95 min (gradient 2); 
1
H NMR (400 MHz, CDCl3): 8.11 & 7.82 (2br, 2H, Ns-H3,6), 
7.77 & 7.60 (2d, J = 7.6 Hz, 4H, Fmoc-H1,4,5,8), 7.71 (m,  2H, Ns-H4,5), 7.40 & 7.32 (2t, J = 7.2 Hz, 
4H, Fmoc-H2,3,6,7), 4.41 (d, J = 6.8 Hz, 2 H, Fmoc-CH2)4.33 (br, 1H, Lys-CH
, 4.21 (t, J = 6.8 Hz, 
1 H, Fmoc-CH), 4.10 (t, J = 6.4 Hz, 2H CH2-CH2-CH3) 3.95  (m, 2 H, Lys-CH2
 ε 1.83 (m, 1H, 
Lys-CH
 β
), 1.73-1.50 (m, 5H, Lys-CH
 β
, CH2-CH2-CH3, Lys-CH2
γ
) 1.38 (m, 2H Lys-CH2
 δt, 
J z, CH2-CH2-CH3). 
13
CNMR(100MHz,CDCl3):
 
ES-MS: calcd (M + H
+
), 595.20; found, m/z 595.31, calcd (M + Na
+
), 617.20; found, m/z 617.45; 
HRMS (ESI) Calcd for C30H33N3O8S, 595.2022; Found, 595.2056. [α] D
 25
  = -7.4 (c = 0.5, CHCl3). 
 
Nα-(9-Fluorenylmethoxycarbonyl)-Nε-diphenylmethyl–N
‘
ε-2-Nitrobenzensulfonyl-L-Lysine 
4f HPLC: tR = 27.25 min (gradient 2); 
1
H NMR (400 MHz, CDCl3):  8.08 & 7.79 (2br, 2H, Ns-
H3,6), 7.76 & 7.58 (2d, J = 7.6 Hz, 4H, Fmoc-H1,4,5,8), 7.68 (m,  2H, Ns-H4,5), 7.39 & 7.39-7.30 (m, 
9H, Fmoc-H2,3,6,7, CH-(Ph)2), 6.88  (s, 1H, CH-(Ph)2), 4.46 (m, 1H, Lys-CH
, 4.40 (d, J = 6.8 Hz, 2 
H, Fmoc-CH2) 4.19 (t, J = 6.8 Hz, 1 H, Fmoc-CH), 2.99 (m, 2 H, Lys-CH2
 ε 1.66-1.26 (4m, Lys-
CHa,b
 β
, Lys-CH2
 γ
,Lys-CH2
 δ13C NMR (100 MHz, CDCl3):   22.27; 29.44; 32.54; 43.89; 47.62; 
54.00; 67.59; 66.40; 78.71; 120.48; 125.58; 125.90; 127.45; 127.59; 127.78; 128.23; 128.68; 
128.85; 129.14; 131.57; 133.21; 134.02; 139.70; 141.80; 144.25; 156.73; 171.80. ES-MS: calcd (M 
+ H
+
), 719.23; found, m/z 719.57, calcd (M + Na
+
), 741.23; found, m/z 741.66; HRMS (ESI) Calcd 
for C40H37N3O8S, 719.2378; Found, 719.2394. [α] D
 25
  = -12.9 (c = 0.3, CHCl3). 
 
Nα-(9-Fluorenylmethoxycarbonyl)-Nε-naphtylmethyl–N
‘
ε-2-Nitrobenzensulfonyl-L-Lysine 
4g HPLC: tR = 26.92 min (gradient 2); 
1
H NMR (400 MHz, CDCl3):  8.06 & 7.85 (2br,  & Ns-
H3,6 ),  7.83 & 7.76 & 7.66 & 7.59 & 7.50 & 7.39 & 7.29 (7m, 17H, Ns-H4,5 , Fmoc-H1,2,3,4,5,6,7,8 , 
Naph-H2,3,4,5,6,7,8 ), 5.29 (m, 2H, CH2-Naph), 4.55-4.40 (m, 3H,  Fmoc-CH2, Lys-CH
, 4.20 (t, 1H, J 
= 6.8 Hz, 1 H, Fmoc-CH), 2.98 (m, 2 H, Lys-CH2
ε 1.66 (m, 1H,  Lys-CH2
β
), 1.52-1.46 (m, 3H,  
Lys-CH2
β
 and Lys-CH2
γ
), 1.30 (m, 2H, Lys-CH2
δ
);
 13
C NMR (100 MHz, CDCl3):  
59 
 
67.58; 68.02; 120.48; 123.15; 125.58; 125.89; 126.37; 
126.98; 127.58; 128.22; 128.51; 129.07; 131.53; 133.20; 133.99; 141.80; 144.13; 156.13; 170.25. 
ES-MS: calcd (M + H
+
), 693.21; found, m/z 693.07, calcd (M + Na
+
), 715.21; found, m/z 715.73; 
HRMS (ESI) Calcd for C38H35N3O8S, 693.2152; Found, m/z 693.2169. [α] D
 25
  = -3.5 (c = 0.4, 
CHCl3). 
 
Nα-(9-Fluorenylmethoxycarbonyl)-Nε-t-butylacetyl–N
‘
ε-2-Nitrobenzensulfonyl-L-Lysine 4h 
HPLC: tR = 23.774 min (gradient 2); 
1
H NMR (400 MHz, CDCl3):  8.12 & 7.81 (2br, 2H, Ns-
H3,6), 7.76 & 7.60 (2d, J = 7.2 Hz, 4H, Fmoc-H1,4,5,8), 7.70 (m,  2H, Ns-H4,5), 7.40 & 7.31 (2t, J = 
7.2 Hz, 4H, Fmoc-H2,3,6,7), 4.68 & 4.44 (2d, J = 10 Hz, 2H, CH2CO2C(CH3)3), 4.56 (d, J = 6.4, 2 H, 
Fmoc-CH2), 4.41 (m, 1H, Lys-CH

)4.21 (t, J = 6.8 Hz, 1 H, Fmoc-CH), 3.11 (m, 2 H, Lys-CH2
 ε 
1.89 & 1.73 (2m, 2H, Lys-CHa,b
 β
), 1.58 (m, 2H, Lys-CH2
 γ
),m, 11H, CH2CO2(CH3)3, Lys-
CH2
 δ13C NMR (100 MHz, CDCl3):  22.17; 28.45; 29.24; 32.29; 43.69; 47.54; 53.79; 62.11; 
67.59; 83.46; 120.42; 125.53; 125.75; 127.53; 128.17; 131.50; 133.11; 133.92; 141.74; 144.13; 
148.51; 156.47; 166.79 172.14. ES-MS: calcd (M + H
+
), 667.22; found, m/z 667.46, calcd (M + 
Na
+
), 689.22; found, m/z 689.81; HRMS (ESI) Calcd for C33H37N3O10S, 667.2200; Found, 
667.2233. [α] D
 25
  = -6.3 (c = 0.4, CHCl3). 
 
Nα-(9-Fluorenylmethoxycarbonyl)-Nε-methyl–N
‘
ε-2-Nitrobenzensulfonyl-L-Lysine 4i HPLC: 
tR = 19.577 min (gradient 2); 
1
H NMR (400 MHz, CDCl3):  8.12 & 7.83 (2br, 2H, Ns-H3,6), 7.76 & 
7.60 (2d, J = 7.2 Hz, 4H, Fmoc-H1,4,5,8), 7.70 (m,  2H, Ns-H4,5), 7.40 & 7.31 (2t, J = 7.2 Hz, 4H, 
Fmoc-H2,3,6,7), 4.40 (d, J = 7.2 Hz, 2 H, Fmoc-CH2)4.31 (m, 1H, Lys-CH
, 4.21 (t, J = 6.8 Hz, 1 
H, Fmoc-CH), 3.74 (s, 3H, Nε-CH3), 3.09 (m, 2 H, Lys-CH2
 ε 1.80 & 1.63 (2m, 2H, Lys-CHa,b
 β
), 
1.56 (m, 2H, Lys-CH2
 γ
) 1.37 (m, 2H, Lys-CH2
 δ13C NMR (100 MHz, CDCl3):  22.42; 29.35; 
32.45; 43.78; 47.54; 53.01; 53.91; 67.57; 120.44; 125.51; 125.83; 127.54; 128.19; 131.48; 133.19; 
134.01; 141.74; 144.14; 148.49; 156.56; 173.19. ES-MS: calcd (M + H
+
), 567.17; found, m/z 
567.11, calcd (M + Na
+
), 589.17; found, m/z 589.26; HRMS (ESI) Calcd for C28H29N3O8S, 
567.1675; Found, 567.1802. [α] D
 25
  = -6.7 (c = 0.5, CHCl3). 
 
Nα-(9-Fluorenylmethoxycarbonyl)-Nε-ethyl–N
‘
ε-2-Nitrobenzensulfonyl-L-Lysine 4j HPLC: 
tR = 20.94 min (gradient 2); 
1
H NMR (400 MHz, CDCl3):  8.12 & 7.83 (2br, 2H, Ns-H3,6), 7.77 & 
7.60 (2d, J = 7.2 Hz, 4H, Fmoc-H1,4,5,8), 7.71 (m,  2H, Ns-H4,5), 7.41 & 7.32 (2t, J = 7.2 Hz, 4H, 
Fmoc-H2,3,6,7), 4.41 (d, J = 6.8 Hz, 2 H, Fmoc-CH2)4.31 (m, 1H, Lys-CH
, 4.21 (m, 3 H, Fmoc-
CH, Nε-CH2CH3), 3.10 (m, 2 H, Lys-CH2
 ε 1.80 & 1.64 (2m, 2H, Lys-CHa,b
 β
), 1.58 (m, 2H, Lys-
CH2
 γ
) 1.39 (m, 2H, Lys-CH2
 δt, J = 7.2 Hz, Nβ-CH2CH3)
13
C NMR (100 MHz, 
CDCl3):  22.47; 29.43; 32.61; 43.87; 47.61; 53.99; 62.23; 67.62; 120.50; 125.58; 125.90; 
127.59; 128.24; 131.56; 133.24; 134.05; 141.81; 144.21; 148.57; 156.62; 172.78. ES-MS: calcd (M 
+ H
+
), 581.18; found, m/z 581.39, calcd (M + Na
+
), 603.18; found, m/z 603.61; HRMS (ESI) Calcd 
for C29H31N3O8S, 581.1832; Found, 581.1864. [α] D
 25
  = -7.1 (c = 0.3, CHCl3). 
 
Nα-(9-Fluorenylmethoxycarbonyl)-Nβ-benzyl–N
‘
β-t-Butoxicarbonyl-L-2,3-Diaminopropionic 
acid 5a HPLC: tR = 24.608 min (gradient 2); 
1
H NMR (400 MHz, CDCl3):   7.77 & 7.60 (2d, J = 
7.6 Hz, 4H, Fmoc-H1,4,5,8), 7.40 & 7.30 (2t, J = 7.6 Hz, 4H, Fmoc-H2,3,6,7), 7.35 (m, 5H, Ph-
H2,3,4,5,6), 5.20 (m, 2H, CH2-Ph), 4.38 (m, 3H, Fmoc-CH2, Dap-CH

), 4.24 (t, J = 6.8 Hz, 1 H, 
Fmoc-CH), 3.59 (br, 2 H, Dap-CH2
s, 9H, C(CH3)3);   
13
C NMR (100 MHz, CDCl3):  
127.50; 128.15; 128.82; 128.98; 129.08; 141.74; 144.16; 156.45; 170.73. ES-MS: calcd (M + H
+
), 
516.23; found, m/z 516,49; calcd (M + Na
+
), 538.23; found, m/z 538,73; HRMS (ESI)  Calcd for 
C30H32N2O6, 516.2260; Found, 516.2291; [α] D
 25
  = -8.3 (c = 0.3, CHCl3). 
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Nα-(9-Fluorenylmethoxycarbonyl)-Nβ-benzyl–N
‘
β-Methylthrityl-L-2,3-Diaminopropionic 
acid 6a HPLC: tR = 29.639 min (gradient 2); 
1
H NMR (400 MHz, CDCl3):   7.68 & 7.58 (1d & 
1m, J = 8 Hz, 4H, Fmoc-H1,4,5,8), 7.33-7.13 (m, 23H, Mtt-(Ph)3, Ph-H2,3,4,5,6, Fmoc-H2,3,6,7), 5.07 (dd, 
2 H, CH2-Ph), 4.30 (m, 1 H, Dap-CH
4.22 (d, J = 6.4 Hz, 2 H, Fmoc-CH2), 4.05 (t, J = 6.4 Hz, 1 
H, Fmoc-CH), 3.47 & 3.29 (2br, 2 H, Dap-CH2
s, 3H, Mtt-CH3);  
13
C NMR (100 MHz, CDCl3):  
127.61; 128.16; 128.32; 128.71;  128.99; 129.06; 134.88; 137.38; 141.62; 143.89; 147.42; 157.25; 
169.35. ES-MS: calcd (M + H
+
), 672.30; found, m/z 672,54; calcd (M + Na
+
), 694.30; found, m/z 
694,08; HRMS (ESI)  Calcd for C31H27N3O8S, 672.2988; Found, 672.3005; [α] D
 25
  = -11.6 (c = 0.3, 
CHCl3). 
 
Nα-(9-Fluorenylmethoxycarbonyl)-Nβ-benzyl–N
‘
β-1-(4,4-dimethyl-2,6-dioxocycloex-1-
ylidene)-3-methylbutyl-L-2,3-Diaminopropionic acid 7a HPLC: tR = 26.381 min (gradient 2); 
1
H NMR (400 MHz, CDCl3):   8.10 (br, 1H, NHα), 7.76 & 7.60 (2d, J = 8 Hz, 4H, Fmoc-H1,4,5,8), 
7.40 & 7.30 (2t, J = 7.2 Hz, 4H, Fmoc-H2,3,6,7), 7.35 (m, 5H, Ph-H2,3,4,5,6), 5.25 (br, 2 H, CH2-Ph), 
4.64 (d, J = 6.4 Hz, 2 H, Fmoc-CH2) 4.39 (m, 1H, Dap-CH

)4.22 (t, J = 6.4 Hz, 1 H, Fmoc-CH), 
3.97 (br, 2 H, Dap-CH2
m, 2H, Dde-CH2CH(CH3)2), 2.42 (s, 4H, Dde-CH2C(CH3)2), 1.89 
(m, 1H, Dde-CH(CH3)2), 1.04 (s, 6H, Dde-C(CH3)2, 0.92 (d, J = 6.8 Hz, 6H, Dde-CH(CH3)2);  
13
CNMR(100MHz,CDCl3):
 125.58; 127.56; 128.24; 129.19; 129.23; 129.40; 134.81; 141.72; 
143.98; 156.21; 169.32; 178.87; 199.43. ES-MS: calcd (M + H
+
), 622.30; found, m/z 622,19; calcd 
(M + Na
+
), 644.30; found, m/z 644,69; HRMS (ESI)  Calcd for C38H48N2O6, 622.3043; Found, 
622.3083; [α] D
 25
  = -9.8 (c = 0.4, CHCl3). 
 
Fmoc-Dap(Ns, Bn)-Ile-OH 8a HPLC: tR = 22.35 min (gradient 2); ES-MS: calcd (M + H
+
), 
714.23; found, m/z 714.08;  
 
H-Dap(Ns, Bn)-Ile-Gly-Gly-Asp-Gly-Asp-Gly-OH 9a Yield: 35%; HPLC: tR = 11.92 min 
(gradient 1); ES-MS: calcd (M + H
+
), 950.36; found, m/z 950.71; 
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